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Summary 
 
 
 
The present manuscript demonstrates that B16F10 melanoma cells activate the enzyme 
acid sphingomyelinase in thrombocytes via the surface molecule P-selectin, by which 
ceramide is released.  Metastasis of tumor cells in the lung is decreased by up to 95% by 
genetic deficiency of P-selectin molecule or deficiency of acid sphingomyelinase.  After 
activation of wild type thrombocytes by B16F10 melanoma cells there is a rapid increase in 
acid sphingomyelinase activity and ceramide production as compared to acid 
sphingomyelinase-deficient thrombocytes or P-selectin-deficient thrombocytes.  A lack of 
interaction of B16F10 melanoma cells and thrombocytes was excluded by activation of PLCγ, 
JNK and MAP kinase, indicating that these signaling events are stimulated in both, wild-type 
and P-selectin-deficient platelets, proving that B16F10 melanoma cells interact with and 
activate P-selectin-deficient thrombocytes.   
 
The molecular mechanisms of tumor metastasis are currently fairly incomplete, though 
metastasis plays a crucial clinical role in cancer patients.  Acid sphingomyelinase is 
iidentified as a novel target molecule for the inhibition of tumor metastasis.  In order to 
pharmacologically inhibit the thrombocytic P-selectin system, an intravenous injection of 
fucoidan showed a decrease of tumor metastasis of B16F10 melanoma cells by approximately 
75%.  This indicates that tumor metastasis can be blocked pharmacologically, which is of 
great clinical interest.   
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1.  Introduction 
 
 
1.1 Tumor Cell- Adhesion Molecule Interaction 
 
1.1.1 Overview of tumor metastasis 
 
Most human cancers are of epithelial origin, and most deaths that result from these 
carcinomas are caused by tumor spread to distant organs, a process known as tumor 
metastasis (Kim et al., 1998).  Tumor metastasis is a multistep cascade during which 
tumor cells have to cross the local extracellular matrix, penetrate the vascular 
endothelium, circulate in the blood (or lymph), and extravasate through vessel walls 
into the tissue for the formation of secondary tumors.  During this process, tumor 
cells associate with cells like leukocytes, platelets, or endothelial cells, acquisition of 
properties that allow this association are of advantage (Friederichs et al., 2000).  It 
may be of particular importance for tumor cells to associate with platelets.  Karpatkin 
et al. (1988) and Mehta et al. (1987) have shown that tumor cells can circulate in the 
vasculature as stabilized platelet- enriched thrombi that can physically protect tumor 
cells from destruction, while the ability to bind to endothelial cells may also be an 
advantage of the tumor cells.  Tumor cells, once in the vasculature, have to bind to 
the endothelial lining of the vessel wall, which is an essential step for tumor 
extravasation and eventual tissue penetration.  A general overview is depicted in Fig.  
1. 
 
 
 
 
 
 
 
 
 
        Introduction 
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Fig. 1 
 
 
 
 
Fig. 1:  General mechanism of tumor metastasis.   
 
Primary tumor cells migrate from the site of origin, enter the blood circulation and interact with 
platelets to form neoplastic emboli that can arrest in the microvasculature and adhere to the 
endothelium.  This adhesion is in part mediated through the action of selectins.  Interaction of tumor 
cells with selectins prevents tumor cell lysis by the immune system. 
 
 
 
1.1.2  Role of P-selectin in tumor metastasis 
 
Tumor cell adhesion to platelets, leukocytes or endothelial cells is in part mediated 
by selectins, a family of cell surface carbohydrate- binding proteins (McEver et al., 
1997; Krause et al., 1999; Kannagi et al., 2004).  Three types of selectins have been 
discovered thus far.  L-selectins (CD62L) are generally expressed on almost all 
leukocytes.  E-selectins (CD62E) are inducible on vascular endothelium upon 
stimulation with cytokines due to transcriptional activation.  P-selectins (CD62P) 
were originally found on activated platelets, but their expression is also induced on 
activated vascular endothelium.  P-selectins are stored as preformed transmembrane 
proteins in cytoplasmic granules (Weibel-Palade bodies of endothelial cells and α-
granules of platelets) which are translocated onto the cell surface upon stimulation by 
cytokines such as Il-1 and TNF-α (Frenette et al., 2000).  L-selectin mediates 
        Introduction 
  3 
adhesion to result in formation of leukocyte-tumor cell emboli as well as local 
secretion of cytokines and growth factors which are thought to aid in secondary 
tumor growth (Qian et al., 2001; Borsig et al., 2002; Rosen et al., 2004), while  E- 
and P-selectin on the endothelium facilitate tumor cells and emboli to anchor in the 
microvasculature (McEver et al., 1997; Krause et al., 1999; Kannagi et al., 1997; 
Hartwell et al., 1999).  P-selectin ligands have been detected previously on several 
human carcinomas and cell lines (Mannori et al., 1995; Aruffo et al., 1992; Stone et 
al., 1993).   
 
Under conditions not involving tumor cells, leukocyte recruitment is integral to 
host defense, during which endothelial selectins mediate tethering (initial 
attachment), rolling of leukocytes for halting circulation of the immune cells to 
extravasate to inflamed tissue (McEver et al., 1995) by binding counter-receptor 
carbohydrate ligands expressed on the surface of leukocytes, and weak attachment of 
the leukocytes onto the vessel wall.  Integrins react with the Ig superfamily of cell 
adhesion molecules for firm adhesion and signal transduction, triggering diapedesis 
and the transendothelial migration of leukocytes (Chen et al., 2006).   This combined 
action of selectins provides a mechanism that enables tumor cells to survive and to 
populate distant organs (Brown et al., 2006). 
 
Functionally, leukocyte rolling serves two main purposes, the successful 
recruitment of neutrophils, monocytes, eosinophils, some effector T-cells and 
dendritic cells to the site of acute and chronic inflammation, and the successful exit 
of T- and B-lymphocytes from high endothelial venules (HEVs) into the parenchyma 
of secondary lymphoid organs (Sperandio, 2006).    Leukocyte rolling is an important 
step in the recruitment of leukocytes into tissue and has been considered to be a 
rather nonspecific process that allows leukocytes to obtain contact with the vascular 
wall (Sperandio, 2006). During rolling, leukocytes have the opportunity to screen the 
endothelial surface for specific trigger signals, leading to a decision for extravasation 
into tissue.    
 
Drastic changes during malignant transformation occur with cell surface 
carbohydrate determinants, and it is well known that expression of sialyl Lewis-x and 
sialyl Lewis-a determinants is significantly enhanced in cancer cells.  These 
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determinants are ligands for the selectins present on endothelial cells and they also 
mediate hematogenous metastasis of tumors.    
 
As a ligand for P-selectin, a mucin-like carbohydrate-presenting molecule P-
selectin glycoprotein ligand 1 (PSGL-1) has been reported (Frenette et al., 2000), 
which has been subject of intensive investigation in the past few years (Vestweber 
and Blanks, 1999) and was first identified on myeloid cells.  PSGL-1 is a homodimer 
or two disulfide-linked subunits of approximately 120 kDa (Moore, 1998; Yang et 
al., 1999) that carries O-linked sialyl-Le-x glycans (Moore et al., 1992; Moore et al., 
1994).  PSGL-1 is expressed on human myeloid HL-60 cells, neutrophils, 
lymphocytes (Moore et al., 1995), CD34+ early progenitor cells (Zanettio et al., 
1995) and other hematopoietic cells, though not always in an active form (Vachino et 
al., 1995).  Cloning of PSGL-1 showed a mucin- like protein with several potential 
sites of O-linked carbohydrates and tyrosine posphorylation (Sako et al., 1993).  
PSGL-1 requires both the specific glycoconjugates sialic acid and fucose, and the 
sulfated tyrosine rsidues for the calcium-dependent recognition by the P-selectin 
lectin domain (Sako et al., 1995; Pouyani and Seed, 1995).  Because PSGL-1 
mediates leukocyte rolling  at physiological shear (Norman et al., 1995), it is a good  
candidate to also mediate platelet rolling.  Frenette et al. (2000) showed that PSGL-1 
mRNA and glycoprotein are expressed in mouse and human platelets, and that 
function-blocking antibody against murine PSGL-1 can inhibit selectin-mediated 
platelet-endothelial interactions in vivo.  Further natural ligands for P-selecin include 
heparin and heparan sulfate proteoglycans (Geng, 2003).  Aigner et al. (1998) have 
identified and characterized another ligand for P-selectin: human CD24 on a breast 
and a small lung carcinoma cell line, KS and SW-2, respectively, can bind to P-
selectin under static conditions (Aigner et al., 1997).  CD24 is a mucin-like 
glycosylphosphatidylinositol-linked cell surface glycoprotein, consisting of a small 
protein core of only 27 extensively glycosylated amino acids (Aigner et al., 1995), 
bound to the membrane via a phosphatidyl inositol anchor (Pirruccello and LeBien, 
1986; Fischer et al., 1990; Kay et al., 1991).  Potential sites for O-linked 
glycosylation are present in nearly half of the CD24 amino acids, composed by serine 
and threonine.  CD24 is highly expressed at the early stages of B-cell development, 
on neutrophils and many human carcinomas, but is absent on T-cells, monocytes or 
normal adult tissue (Akashi et al., 1994; Jackson et al., 1992; Pirruccello and LeBien, 
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1986).  Aigner et al. (1998) showed that CD24 can function as a physiological 
counter receptor for P-selectin and mediate rolling of the breast carcinoma cell line 
KS.  
 
 
1.1.3  Fucoidan as a ligand for P-selectin 
 
In arterial thrombogenesis, plaque rupture followed by the formation of a thrombus 
is a fundamental pathophysiology of acute coronary syndromes (Fuster et al., 1988), 
in which platelets are a major component of these thrombi. Current treatment 
includes anti-platelet drugs like aspirin, and inhibition of specific platelet integrin 
receptor glycoprotein IIb/IIIα has been shown to inhibit platelet aggregation and 
thrombus formation by the prevention of platelet-platelet interaction (Shattil et al., 
1985.  Yokoyama et al. (2005) have shown that inhibition of P-selectin function by 
monoclonal antibody to P-selectin reduces platelet-mediated thrombus formation 
(Ueyama et al., 1997; Ikeda et al., 1999), and in a canine model the incorporation of 
platelets with upregulated P-selectin to leukocytes in large arterial thrombi of acute 
coronary syndromes was shown (Ikeda et al., 1999).  Therefore, platelet P-selectin 
plays an important role in arterial thrombogenesis by forming large stable platelet-
leukocyte aggregates.  Thorlacius et al. (2000) showed that the polysaccharide 
fucoidan has anticoagulative properties in terms of thrombin clotting time 
prolongation, and it has been suggested that this anticoagulative effect is mainly due 
to enhanced thrombin inhibition by different mechanisms (Colliec et al., 1991; 
Church et al., 1989; Nishino et al., 1991).  Other references propose the 
anticoagulative effect being due to fucoidan primarily stimulating the release of 
tissue factor pathway inhibitor from endothelial cells (Giraux et al., 1998).  Fucoidan 
is known to bind and interfere with the activity of both P- and L-selectin (Bevilacqua 
and Nelson, 1993; Nelson et al., 1993), thereby causing the antithrombotic effect of 
fucoidan in vivo.  Thorlacius et al. (2000) show that fucoidan effectively prevents 
microvascular thrombus formation induced by endothelial damage in arterioles and 
venules in vivo; however, this protective effect of fucoidan cannot be attributed to the 
inhibition of either P-selectin or L-selectin function but instead may be related to the 
anticoagulative capacity of fucoidan.  Fucoidan drastically delayed the progression of 
thrombus growth and the time required for complete vessel occlusion.    
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1.1.4  P-Selectin in inflammation and thrombosis 
Inflammation and thrombosis play major roles in atherosclerosis pathogenesis. 
Activated endothelial cells release Weibel-Palade bodies, granules that contain 
procoagulant and proinflammatory substances including multimeric von Willebrand 
factor (vWF), P-selectin, and CD63 (Wagner et al., 1982; Bonfanti et al., 1989; 
Vischer and Wagner, 1993; Datta and Ewenstein, 2001; Wagner, 1993).  Interleukin-
8 (IL-8), thromboplastinogen, calcitonin gene–related peptide, and endothelin have 
been reported in Weibel-Palade bodies as well (Utgaard et al., 1998; Ueda et al., 
1992; Ozaka et al., 1997; Schaumburg-Lever et al., 1994).  Exocytosis of Weibel-
Palade bodies is triggered by a variety of agonists, including thrombin, histamine, 
complement, leukotrienes, superoxide anions, epinephrine, adenosine, and 
vasopressin (Birch et al., 1992; Hamilton and Sims, 1987; Hattori et al., 1989; 
Vischer et al., 1995; Vischer and Wollheim, 1997).  Weibel–Palade body exocytosis 
is mediated by calcium, cAMP, and G-proteins (Birch et al., 1992; Hamilton and 
Sims, 1987; Vischer and Wollheim, 1997; Klarenbach et al., 2003). After Weibel–
Palade body exocytosis, P-selectin is translocated to the endothelial surface, where it 
facilitates leukocyte rolling, and vWF is released into the vessel lumen, where it 
mediates platelet adhesion and aggregation (Ramos et al., 1999; Andre et al., 2000). 
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1.2   Sphingomyelin, Ceramide and Sphingosine-1-Phosphate  
 
1.2.1  Overview of ceramide function 
Sphingolipids found in plasma membranes of all eukaryotic cells play an 
important signaling role in vascular inflammation and thrombosis (Hannun and 
Obeid, 2002; Auge et al., 2000; Levade et al., 2001). The sphingolipid ceramide 
mediates a variety of stress responses (Hannun, 1996).  Ceramide is produced de 
novo from serine condensation with palmitoyl-coenzyme A in the endoplasmic 
reticulum or from hydrolysis of sphingomyelin by sphingomyelinase in the plasma 
membrane, lysosomes, or endoplasmic reticulum (Huwiler, 2000).  A variety of 
factors induce ceramide production, including tumor necrosis factor-α (TNF-α), IL-
1ß, interferon-γ, CD95 ligand, B7, CD40 ligand, oxidized low-density lipoprotein 
(LDL), ischemia, radiation, and chemotherapeutic agents (Hannun and Obeid, 2002; 
Auge et al., 2000; Levade et al., 2001; Hannun, 1996).   Ceramide and its 
metabolites mediate inflammation, thrombosis, apoptosis, cell differentiation, 
proliferation, and vasomotor regulation by changing the biophysical properties of the 
cell membrane and the distribution of receptors in the membrane as well as by acting 
on a variety of phosphatases, proteases, kinases, phospholipases, and transcription 
factors (protein phosphatase [PP] 1, PP2A, cathepsin, protein kinases, endothelial 
differentiation gene receptors, NF-κB, mitogen-activated protein kinase, 
plasminogen activator inhibitor-1 (PAI-1), nicotinamide adenine dinucleotide 
phosphate oxidase, and endothelial nitric oxide synthase [NOS]) (Kupatt et al., 1997; 
Qian et al., 2001; Hannun and Obeid, 2002; Auge et al., 2000; Levade et al., 2001; 
Hannun, 1996; Igarashi et al., 1999; Dantas et al., 2003; Gonzalez et al., 2002; Kou 
et al., 2002; Igarashi et al., 2001a; Igarashi et al., 2001b; Igarashi and Michel, 2000).  
Ceramide can induce vascular inflammation by activating transcriptional pathways, 
but ceramide can also rapidly trigger vascular inflammation by nontranscriptional 
pathways, although the precise mechanism by which it does so is unclear.  
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1.2.2  Ceramide-enriched membrane platforms 
 
The sphingomyelin pathway is a signaling system that is conserved from yeast 
to humans (Peña et al., 1997; Hannun, 1996; Spiegel et al., 1996; Ballou et al., 
1996).  Membrane sphingomyelin is hydrolyzed by at least three different 
sphingomyelinases, which are characterized by their optimal pH: acid, neutral and 
alkaline.  The product of the enzymatic action is ceramide, which is the amide 
ester of the sphingoid base D-erythrosphingosine and a fatty acid ranging from C2 
to C28, but usually from C16 to C26 chain length.  The best-characterized 
sphingomyelinase is the enzyme acid sphingomyelinase.  Acid sphingomyelinase 
is a 75 kDa protein that is post-translationally modified by glycosylation, which is 
necessary for its functionality (Newrzella and Stoffel, 1996; Ferlinz, 1997).  As 
the acid sphingomyelinase is produced, at least two forms of the enzyme are 
formed: a lysosomal and a secretory form. An isoform that binds to the cell 
surface might be a third independent isoform or either lsosomal or secretory acid 
sphingomyelinase. Although derived from the same gene, the lysosomal and 
secretory forms are differently glycosylated and processed at the NH2-terminus.  It 
is this glycosylation pattern that most likely determines the targeting of the two 
enzymatic forms of the acid sphingomyelinase to different cellular compartments, 
and all forms of the enzyme appear to have different functions (Gulbins, 2003).  In 
acidic compartments like late endosomes and lysosomes the enzyme regulates 
sphingomyelin turnover, where the secretory form is involved in stress, 
inflammation and regulation of serum lipoproteins (Schissel et al, 1996; Schissel 
et al., 1998a; Schissel et al., 1998b; Tabas, 1999).  The surface form of the 
enzyme is important for the regulation of receptor and signalling protein 
distribution involved, for instance, in apoptosis.  This form has been shown to 
appear on the cellular surface upon cellular stimulation by CD95 (Grassmé et al., 
2001a; Grassmé et al., 2001b) or CD40 (Grassmé et al, 2002).  CD95 is a pro-
apoptotic molecule, and several pro-apoptotic molecules like TNF-R or stress 
stimuli like UV-light (Chatterje and Wu, 2001) or irradiation (Santana et al., 1996; 
Pena et al., 1996; Paris et al., 2001) have been shown to activate the acid 
sphingomyleinase rapidly (within seconds to minutes), resulting in the release of 
extracellularly oriented ceramide and the formation of ceramide-enriched 
membrane platforms (Fig. 2 A+B). 
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Fig. 2 A: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 B: 
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Fig. 2 A+B:  Schematic representation of ceramide-enriched membrane platform formation 
through receptor clustering.   
 
A: When stimulated, the cellular acid sphingomyelinase is activated and generates ceramide from 
sphingomyelin.  Ceramide accumulation leads to platform formation on the cellular surface, 
causing aggregation of the receptors and intracellular signaling proteins within the platforms.  This 
aggregation leads to an amplification of signal and the transmission of those signals into the cell.   
B: The chemical structure of sphingomyelin that is hydrolyzed by action of the enzyme acid 
sphingomyelinase, leading to the release of ceramide and phosphorylcholine (from Gulbins and Li, 
Am J Physiol Regul Integr Comp Physiol, 2006). 
 
 
 
Singer and Nicholson showed (Singer and Nicholson, 1972) that membranes are 
not static but consist in a fluid-mosaic state, known as the fluid-mosaic model.  In 
recent years, this model has been modified to include findings that lipids can 
spontaneously be organized into distinct microdomains of the cellular membrane 
(Anderson, 1998; Brown and London, 1998; Simons and Ikonen, 1997).  The 
cellular membrane is mainly composed of glycerophospholipids, sphingolipids, 
and cholesterol.  The sphingolipid headgroups cause a lateral association of lipids 
with one another, further enhanced by hydrophobic interactions between the 
saturated side chains, while cholesterol appears to fill the spaces between the large 
glycerosphingolipids and tightly interacts with sphingolipids, especially 
sphingomyelin (Gulbins and Kolesnick, 2003).  This interaction results in the 
separation of the lipids into distinct membrane structures characterized by a 
liquid-ordered phase, while the glycerophospholipids in the cell membrane are 
located in a rather fluid liquid phase (Simons and Ikonen, 1997; Brown and 
London, 1998).  Because sphingomyelin is almost exclusively located in the 
anticytosolic leaflet of biological membranes (Emmelot and Van Hoeven, 1975), 
rafts also appear to be present predominantly in the outer leaflet of the cell 
membrane and the anti-cytostolic leaflet of intracellular membranes (Gulbins and 
Li, 2006).  Rafts- the term refers to these microdomains seemingly floating in an 
“ocean” of other glycerophospholipids of the cellular membrane- range in size 
between 30 and 300 nm, and the consumption of sphingomyelin within rafts to 
generate ceramide results in drastic change within these small rafts.  Ceramide 
fuses membranes and has the ability to form large ceramide-enriched membrane 
platforms excluding cholesterol.  Holopainen et al. (1998) and Nurminen et al. 
(2002) showed that ceramide generation was followed by the formation of patches 
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of ceramide that associated rapidly into a ceramide-enriched macrodomain, 
suggesting that this fusion function resulted from hydrogen bonding and van der 
Waal forces between ceramide molecules. 
 
 
1.2.3  Ceramide generation from sphingomyelin via acid sphingomyelinase  
 
As acid sphingomyelinase is activated by various stimuli including CD95 or 
CD40, infection with Pseudomonas aeruginosa, Staphylococcus aureus, gamma 
irradiation or heat, the enzyme is rapidly translocated to the extracellular leaflet of 
the cell membrane.  Gulbins and Kolesnick (2003) suggested that rapid fusion of 
intracellular vesicles containing acid sphingomyelinase with the cellular 
membrane occurs upon contact with these diverse stimuli, resulting in exposure of 
acid sphingomyelinase on the cellular surface.  This surface acid 
sphingomyelinase appears to localize to rafts and releases ceramide from 
sphingomyelin, which in turn transforms rafts into large ceramide-enriched 
signaling platforms, reaching the size of several μm in diameter (Gulbins and 
Kolesnick, 2003).  These platforms serve to trap and cluster receptor molecules 
like CD95 or CD40; furthermore, these ceramide-enriched membrane platforms 
seem to be involved in the cellular response to radiation, UV-A light, heat, some 
chemotherapeutics and infections with pathogenic bacteria and viruses (Gulbins 
and Kolesnick, 2003).  Clustering of CD95 results in high local density of the 
receptor in a small area of the cellular surface, allowing for clustering of the 
receptors and eventually also of downstream effector molecules.  Rapid clustering 
of CD95 upon stimulation has been shown in lymphocytes, phagocytic cells, 
epithelial cells, fibroblasts, hepatocytes and thymocytes (Fanzo et al., 2003).    
 
Ceramide activates a diverse set of protein kinases and protein phosphatases 
(Smyth et al., 1997; Hannun, 1996; Ruvolo, 2001), involving the SAPK/JNK 
signaling pathway in apoptosis, the kinase supressor of Ras (KSR) and protein 
kinase C (PKC).  Ceramide redirects cellular signaling pathways by promoting 
SAPK cascades at the expense of MAPK pathways (Jarvis et al., 1997).  
Activation of SAPK pathways induces cell cycle arrest and inhibits cell 
        Introduction 
  12 
proliferation (Bourbon et al., 2000), therefore ceramide generation conditions 
promote JNK activation (Ruvolo, 2003).   
 
The generation of those ceramide-enriched membrane domains results in a re-
organization of the cell membrane, re-ordering of receptor molecules, clustering 
of receptors, trapping of receptors and intracellular signaling proteins and thereby 
transmission of signals into the cell.  Ceramide may also influence the 
permeability of cell membranes (Kolesnick and Kronke, 1998; Ruiz-Arguello et 
al., 1996) since ceramide can form pores that allow efflux of 20-60 kDa molecules 
(Siskind and Colombini, 2000; Siskind et al., 2002; Montes et al., 2002). 
 
 
 
1.2.4   Sphingosine and sphingosine-1-phosphate as ceramide metabolites 
 
The metabolites of ceramide, sphingosine and sphingosine-1-phosphate, were 
shown to be intracellular mediators regulating cell proliferation or apoptosis 
(Hannun, 1994; Hannun and Obeid, 1995; Kolesnick and Golde, 1994; Cubillier et 
al., 1996; Olivera and Spiegel, 1993; Spiegel and Milstien, 1995).  Sphingosine-1-
phosphate is the initial product of the catabolism of sphingosine by action of 
sphingosine kinase, and is then cleaved by sphingosine lyase to yield 
ethanolamine phosphate and a fatty aldehyde (Spiegel et al., 1996; Spiegel and 
Milstien, 1995; Van Veldhoven and Mannaerts, 1991).   It has been revealed that 
sphingosine-1-phosphate is a ligand for G-protein-coupled receptors (AGR), 
endothelial  differentiation gene 1 (EDG1) (Lee et al., 1998; Okamoto et al., 1998; 
Zondag et al., 1998), EDG3 (An et al., 1997; Okamoto, 1999), AGR16/EDG5 
(Gonda et al., 1999), which indicates that sphingosine-1-phosphate works 
extracellularly as well as within the cell to evoke biological responses (Van 
Brocklyn et al., 1998).  Notably, it has been shown that sphingosine-1-phosphate 
is abundantly stored in platelets (Yatomi et al., 1995a) and released upon platelet 
activation (Yatomi et al., 1995b).  In terminally differentiated platelets, 
sphingosine-1-phosphate induces a shape change and aggregation by itself, and 
synergistically elicits aggregation in combination with weak platelet agonists such 
as epinephrine and adenosine diphosphate (ADP) (Yatomi et al., 1995b).  Yatomi 
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et al. (1997) reported that sphingosine-1-phosphate is released from platelets into 
the serum during the blood clotting process, suggesting that sphingosine-1-
phosphate release from activated platelets renders platelets to act as producers 
(from sphingosine) and releasers of sphingosine-1-phosphate in vivo. 
Additionally, sphingosine-1-phosphate has been shown to be involved in a variety 
of cellular functions including the stimulation of fibroblast growth (Zhang et al., 
1991; Olivera and Spiegel, 1993), regulation of cell motility (Sadahira et al., 
1992; Bornfeldt et al., 1995), activation of muscarinic K+ currents in atrial 
myocytes (Bunemann et al., 1995; van Koppen et al., 1996), and suppression of 
ceramide-mediated apoptosis (Cuvillier et al., 1996).   
 
In contrast to the well-characterized function of sphingosine-1-phosphate in 
platelets, very little is known about sphingosine in platelets.  It might be possible 
that sphingosine is a metabolite very rapidly converted to either sphingosine-1-
phosphate, ceramide, or that it is degraded.   
 
Fig. 3: 
 
(from Tani et al., J Lip Res, 2005) 
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Fig. 3:  Scheme for the mechanism of sphingosine and sphingosine-1-phosphate generation in 
human platelets.   
 
Cer: ceramide; SM: sphingomyelin; SMase: sphingomyelinase; Sph: sphingosine; S1P: 
sphingosine-1-phosphate (from Tani et al., J Lip Res, 2005). 
 
 
 
 
1.3  Programmed Cell Death 
 
1.3.1  Role of ceramide in apoptosis- the extrinsic pathway 
 
Most studies on ceramide focused on cell death, which will be briefley discussed 
although cell death is not the primary focus of this discussion.  The process of cell 
death involves programmed events regulated by specific biochemical pathways 
(Taha et al., 2006).  Programmed cell death is driven by complex pathways 
involving several players, and can essentially be subdivided into three stages: a) 
intitation, b) commitment, and c) execution (Taha et al., 2006).  The first step 
often occurs at or in the proximity of the cellular compartment where stress is 
induced  (Feng and Hannun, 1998), like, for instance, disruption of Ca2+ 
homeostasis at the level of the endoplasmic reticulum, which leads to calcium-
induced cell death (Breckenrisge et al., 2003).  This is turn causes the genotoxic 
stress in the nucleus to induce p53-driven cell death pathway activation (Miyashita 
and Reed, 2003; Oda et al., 2000; Yu et al., 2001; Nakano and Vousden, 2001).  A 
further initiator of programmed cell death is the activation of cell death receptors 
at the level of the plasma membrane, involving the downstream activation of one 
or more organelle-mediated pro-apoptotic pathways (Jaattela, 2004; Barnhart et 
al., 2003).  After biochemical pathways have been activated, triggered by a death 
signal, the cell converges onto the commitment step that may, in several instances, 
occur at the mitochondrial level (Ferri and Kroemer, 2001).  Once the 
mitochondrion receives the death signal, a major mitochondrial change occurs, the 
mitochondrial membrane permeabilization, which, at the level of the outer 
mitochondrial membrane, causes the release of several proteins from the 
intermembrane space into the cytosolic space (Taha et al., 2006).  Oligomerization 
of the adapter molecule APAF-1 is triggered by the release of cytochrome c,  
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causing the activation of caspase 9 (an integral cysteine protease in the 
mitochondrial cellular death pathway (Sellers and Fisher, 1999).  Caspase 9 in 
turn activates caspases 3 and 7, members of the execution phase of programmed 
cell death that cleave proteins essential to normal cell function (Wolf and Green, 
1999).   A further protein that is released from mitochondria is Smac/Diablo (Taha 
et al., 2006), which binds to inhibitors of apoptosis that usually function to keep 
caspases from activation.  As cytochrome c and Smac are released, the cell shows 
typical features of apoptotic death, including chromatin condensation and 
externalization of phosphatidylserine. 
 
 
1.3.2  Role of mitochondria in apoptosis- the intrinsic pathway of apoptosis 
 
Alternative forms of programmed cell death can be activated by release of 
different mitochondrial proteins that are caspase-independent.  After 
mitochondrial membrane permeabilization, the proteins apoptosis-inducing factor 
(Gallego et al., 2004) and endonuclease G (Hahn et al., 2004) translocate from the 
mitochondrion to the nucleus, causing caspase-independent loose chromatin 
condensation (Taha et al., 2006).  A further alternative form of cell death is 
comprised in the release of HtrA2/Omi, displaying a dual role in cell death in that 
the complex causes inhibitor of apoptosis inactivation, and displays serine 
protease activity (Hegde et al., 2002).   
 
An entire family of proteins that is involved in the control of mitochondrial 
function in apoptosis is the members of the Bcl-2 family, which can be subdivided 
into three distinct classes: the Bcl-2-like survival factors like Bcl-2 and Bcl-xL that 
maintain mitochondrial integrity (their overexpression guards the mitochondrion 
against stimuli normally inducing mitochondrial membrane permeabilization); the 
Bax-like death factors like Bax and Bad; and the BH3-only death factors such as 
Noxa, Puma, Bid, Bad, and Bik (Borner, 2003).  The latter two subgroups 
compromise mitochondrial function and mediate cell death by several stimuli that 
induce mitochondrial membrane permeabilization, therefore indicating that the 
integrity of the cell and therefore the survival of the cell is dependent on the 
balance between the proapoptotic and the antiapoptotic Bcl-2 family members. 
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There are various reports showing the position of ceramide with respect to Bcl-2 
proteins in that some groups have reported that ceramide acts upstream of Bcl-2 in 
the apoptotic pathway because of cell death rescue by Bcl-2 overexpression 
induced by ceramide (Zhang et al., 1996) or ceramidase inhibitors (Raisova, 
2002).  Also, it has been shown (El-Assaad et al., 1998) that Bcl-xL proteins 
rescue the cells from TNF-mediated cell death.  This suggests that ceramide is 
involved in the cell death pathway downstream of Bcl-xL; however, other studies 
have shown that overexpression of Bcl-2 and Bcl-xL inhibits ceramide 
accumulation as a result of DNA damage stimulus (Tepper et al., 1999; El-Assaad 
et al., 1998; Sawada et al., 2000), implying that Bcl-2 can also act upstream of 
ceramide in the cell death pathway.  Taha et al. (2006) suggested that not all 
ceramide species generate the same responses in regard to fatty acid chain length 
of ceramide, and that the different biological effects caused by ceramide may be 
mediated by distinct molecular species of the lipid (Taha et al., 2006).   
 
Fig. 4 A+B: 
 
Fig. 4 A+B: Sphingosine and sphingosine-1-phosphate in apoptosis.   
 
A:  Cellular death is mediated through sphingosine by inhibiting the prosurvival factors PKC and 
Akt/PKB; cellular death is induced by SDK1, leading to activation of Bax by inhibiting the 
proteins 14-3-3.  B:  Apoptosis is inhibited by sphingosine-1-phosphate through activation of 
prosurvival factors like Akt/PKB, NF-κB, ERK and nitric oxide.  Inactivation of JNK or other 
factors promoting programmed cellular death may also inhibit ceramide-induced cell death by 
sphingosine-1-phosphate.  (from Taha et al., Biochim Biophys Acta, 2006) 
 
 
 
(from Taha et al., Biochim Biophys Acta, 2006) 
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Experiments by Gudz et al. (1997) have revealed that several changes in isolated 
mitochondria can be induced by ceramide in vitro (Gudz et al., 1997).  C2-
ceramide inhibited oxidative phosphorylation by electron transport chain 
interference at the level of complex III, and ceramide also increases the 
permeabiliy of the outer mitochondrial membrane to several proteins including 
cytochrome c (Siskind et al., 2002).  Furthermore, Novgorodov et al. 
(2006) demonstrated that ceramide is able to enhance the permeability of the inner 
mitochondrial membrane by action of the permeability transistion pore and the 
electrogenic proton channel, enhancing the release of solutes into the cytosol 
(Novgorodov et al., 2006). It was shown by Lorusso et al. and Di Paola et al., 
2004) that ceramide induces cytochrome c release from isolated mitochondria in a 
permeability transition pore-dependent and independent manner, and Ghafourifar 
et al. (1999) showed that ceramide maintains cytochrome c in an oxidized state 
which seems to be necessary for reducing mitochondrial oxygen consumption and 
releasing calcium from mitochondria.  Therefore, it appears that there is a direct 
effect of ceramide on mitochondria.  Further investigation into sphingomyelin 
hydrolysis specific to organelles has revealed that only ceramide generation at the 
mitochondrial level can cause cell death, while its formation in other organelles 
fails to do so (Birbes et al., 2001). 
 
 
1.4   Aims of the Study 
 
The present study will aim to identify the function of acid sphingomyelinase in 
platelets as crucial for for hematogenous metastasis of melanoma cells into the 
lung.  The interaction of tumor cells with platelets and a possible activation of the 
enzyme acid sphingomyelinase that results in a release of ceramide from platelets 
was studied.  Furthermore, knock-out mice deficient for acid sphingomyelinase 
were employed to define the biological function of the acid sphingomyelinase for 
tumor metastasis in vivo. 
 
Furthermore, this study aims to show whether activation of acid sphingomyelinase 
by melanoma cells is mediated by the P-selectin molecule present on platelets and 
abrogated in platelets deficient for the P-selectin molecule.  Studies were carried 
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out to determine whether P-selectin-deficient platelets still interact with tumor 
cells.  To this end, tyrosine phosphorylation induction of several cellular 
substrates was investigated in both, wild-type and P-selectin-deficient platelets.  
To determine whether P-selectin activation occurs upstream of acid 
sphingomyelinase activation or vice versa, platelet degranulation and P-
selectin/GPIIβIIIα expression after stimulation with B16F10 melanoma cells will 
be investigated in wild-type and ASM-deficient platelets; analysis thereof will 
also indicate whether P-selectin itself prevents activation of thrombocytes by 
B16F10 melanoma cells.  Finally, it was determined whether fucoidan, a natural 
ligand of P-selectin, is able to prevent melanoma metastasis in wild-type mice. 
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2. Materials and Methods 
 
 
2.1 Materials 
 
2.1.1 Chemicals and Enzymes 
 
Unless otherwise noted, all chemicals and enzymes were purchased from Sigma, Roth, 
Gibco, Serva, Fluka, J.T. Baker, Amersham, Invitrogen, Perkin-Elmer or Merck.  
Radioactive compounds were purchased from Perkin-Elmer or Hartmann Analytics.  The 
following table of chemicals including radioisotopes and enzymes indicates the name of 
the chemical and the source from where it was obtained. 
 
 
Chemical Name Source 
  
  
2-Mercaptoethanol Sigma-Aldrich Chemie GmbH, Steinheim 
Acetic Acid  Merck, Darmstadt 
Agarose Gibco/Invitrogen, Karlsruhe 
Albumin Fraction V, Fatty-Acid free Carl Roth GmbH&Co., Karlsruhe 
Aprotinin Sigma-Aldrich Chemie GmbH, Steinheim 
ATP Sigma-Aldrich Chemie GmbH, Steinheim 
Boric Acid Sigma-Aldrich Chemie GmbH, Steinheim 
Bromophenol Blue Serva Electrophoresis GmbH, Heidelberg 
C16 Ceramide BioMol, PA, USA 
Calcium Chloride Sigma-Aldrich Chemie GmbH, Steinheim 
Cardiolipin Sigma-Aldrich Chemie GmbH, Steinheim 
CDP-Star Tropix 
Chloroform Riedel-de-Haen, Seelze 
DAG Kinase Amersham 
Diethylenetriaminepentaacetic acid, DETAPAC Sigma-Aldrich Chemie GmbH, Steinheim 
Dithiothreitol, DTT Carl Roth GmbH&Co., Karlsruhe 
EGTA Carl Roth GmbH&Co., Karlsruhe 
Ethanol Fluka Chemie GmbH, Buchs 
Ethidium Bromide Serva Electrophoresis GmbH, Heidelberg 
Ethylenediaminetetraacetic acid, EDTA Serva Electrophoresis GmbH, Heidelberg 
Fucoidan Sigma-Aldrich Chemie GmbH, Steinheim 
Glucose Sigma-Aldrich Chemie GmbH, Steinheim 
Glycine Carl Roth GmbH&Co., Karlsruhe 
Hydrochloric Acid J.T. Baker 
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Imidazole-HCl Sigma-Aldrich Chemie GmbH, Steinheim 
Isopropanol J.T. Baker 
Leupeptin Sigma-Aldrich Chemie GmbH, Steinheim 
Magnesium Chloride Sigma-Aldrich Chemie GmbH, Steinheim 
Magnesium Sulfate Sigma-Aldrich Chemie GmbH, Steinheim 
Methanol Fluka Chemie GmbH, Buchs 
n-Octylglucopyranoside Sigma-Aldrich Chemie GmbH, Steinheim 
NP-40 Sigma-Aldrich Chemie GmbH, Steinheim 
Potassium Chloride Sigma-Aldrich Chemie GmbH, Steinheim 
Proteinase K Sigma-Aldrich Chemie GmbH, Steinheim 
Scintillation Liquid Beckman-Coulter, Fullerton, CA, USA 
Sodium Acetate Sigma-Aldrich Chemie GmbH, Steinheim 
Sodium Carbonate Sigma-Aldrich Chemie GmbH, Steinheim 
Sodium Chloride Carl Roth GmbH&Co., Karlsruhe 
Sodium Citrate Sigma-Aldrich Chemie GmbH, Steinheim 
Sodium Deoxycholate Sigma-Aldrich Chemie GmbH, Steinheim 
Sodium Dodecyl Sulfate, SDS Sigma-Aldrich Chemie GmbH, Steinheim 
Sodium Fluoride Sigma-Aldrich Chemie GmbH, Steinheim 
Sodium Orthovanadate Sigma-Aldrich Chemie GmbH, Steinheim 
Sodium Phosphate Sigma-Aldrich Chemie GmbH, Steinheim 
Sodium Pyrophosphate Sigma-Aldrich Chemie GmbH, Steinheim 
Tris-HCl Carl Roth GmbH&Co., Karlsruhe 
Triton X-100 Sigma-Aldrich Chemie GmbH, Steinheim 
Tween Sigma-Aldrich Chemie GmbH, Steinheim 
 
 
2.1.2 Tissue Culture Materials 
 
Dissociation Buffer, Enzyme-free Gibco/Invitrogen, Karlsruhe 
Fetal Bovine Serum, FBS Gibco/Invitrogen, Karlsruhe 
HEPES Carl Roth GmbH&Co., Karlsruhe
L-Glutamine Gibco/Invitrogen, Karlsruhe 
MEM Medium Gibco/Invitrogen, Karlsruhe 
Non-Essential Amino Acids Gibco/Invitrogen, Karlsruhe 
Penicillin Gibco/Invitrogen, Karlsruhe 
Sodium Pyruvate Gibco/Invitrogen, Karlsruhe 
Streptomycin Gibco/Invitrogen, Karlsruhe 
T75 Tissue Culture Flasks TPP, Trasadingen, Switzerland 
Trypsin Gibco/Invitrogen, Karlsruhe 
 
 
2.1.3 Radioactive Compounds 
 
[32P]- γ- ATP    Hartmann Analytic, Braunschweig 
[14C]- Sphingomyelin   Perkin-Elmer, Boston, MA, USA 
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2.1.4 Common Solutions used 
 
10x TBS-Tween  200 mM Tris-Cl pH 7.4 
    1.5 M NaCl 
    1% Tween 
 
Protein Transfer Buffer 25 mM Tris 
    192 mM Glycine 
    20% Methanol 
 
Tissue Lysis Buffer  1x PCR buffer (Solis) 
    0.5 mM MgCl2 
    0.045% Tween-20 
    0.045% IGEPAL 
    300 μg/ml Proteinase K 
 
10x HEPES-Saline  200 mM HEPES 
    1.32 M NaCl 
    10 mM CaCl2 
    7 mM MgCl2 
    8 mM MgSO4 
    54 mM KCl 
 
1x TBE   90 mM Tris-Acetate pH 7.8 
    10 mM Boric Acid 
    1 mM EDTA 
 
1x PBS   137 mM NaCl 
    2.6 mM KCl 
    6.5 mM Na2HPO4 
    1.5 mM KH2PO4 
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Ethidium Bromide  10 mg/ml Ethidium Bromide in H2O 
 
5x SDS Sample Buffer 250 mM Tris pH 6.8 
    20% Glycine 
    4% SDS 
    8% 2-Mercaptoethanol 
    0.2% Bromophenol blue  
 
6x DNA Loading Buffer 50% Glycerol 
    0.02% Bromophenol blue 
    0.04% Xylene Cyanol 
    1mM EDTA 
 
SDS-PAGE                             Solution A: 40% Acrylamide (39.2g Acrylamide /100                                
                                                                                    ml; 0.8 g Bis-Acrylamide /100 ml) 
                                    Solution B: 3M Tris pH 8.8 
                                    Solution C: 3M Tris pH 6.8 
Tyrode Buffer   20 mM HEPES pH 7.4 
    134 mM NaCl 
    2.9 mM KCl 
    12 mM NaHCO3 
    1 mM CaCl2  
    5 mM Glucose  
Alkaline Wash Buffer 100 mM Tris pH 9.5 
    100 mM NaCl 
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2.1.5  Oligonucleotide Primers used for Genotyping 
 
The utilized ASM DNA oligonucleotides were purchased from Hermann GbR 
Freiburg, the oligonucleotides for mycoplasma were from MWG Biotech. 
 
ASM-PA1-2:   5’- CGAGACTGTTGCCAGACATC -3’ 
 
ASM-PA2-2:   5’- GGCTACCCGTGATATTGCTG -3’ 
 
ASM-PS-2:   5’- AGCCGTGTCCTCTTCCTTAC -3’ 
 
Mycoplasma sense:  5’- GTGCCAGCAGCCGCGGTAATA -3’ 
 
Mycoplasma antisense: 5’- TACCTTGTTACGACTTCACCCCA -3’ 
 
 
2.1.6  Antibodies  
 
For Western Blot protein analysis the following primary and secondary antibodies were 
utilized: 
 
Primary Antibodies 
 
PE- conjugated rat-anti-mouse Glycoprotein αIIbβ3 (emfret analytics) 
FITC- conjugated rat-anti-mouse P-Selectin CD62P (emfret analytics) 
Phospho-P44/42 MAP Kinase (T202/Y204) E10 Monoclonal antibody (Cell Signaling) 
Phospho- SAPK/JNK (Thr183/Tyr185) Antibody (Cell Signaling) 
Anti-Phosphotyrosine Clone 4G10 Mouse Monoclonal IgG Antibody (Upstate) 
Anti-PLCγ-1 Clone B-6-4 Mouse Monoclonal IgG Antibody (Upstate) 
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Secondary Antibodies 
 
All secondary antibodies were purchased from Santa Cruz 
 
Anti-Goat IgG-Alkaline Phosphatase-coupled  
Goat-anti-Rabbit IgG Alkaline Phosphatase-coupled  
Goat-anti-Guinea Pig IgG Alkaline Phosphatase-coupled 
Goat-anti-Mouse IgG Alkaline Phosphatase-coupled 
 
For flow cytometry experiments the above mentioned antibodies 
 
PE- conjugated rat-anti-mouse Glycoprotein αIIbβ3 and  
FITC- conjugated rat-anti-mouse P-Selectin CD62P 
 
were used. 
 
 
 
2.2 Organisms 
 
Wild-type C57/Bl6 mice and P-Selectin-deficient mice were obtained from Jackson 
Laboratories; the ASM-deficient mice were provided by Dr. Richard Kolesnick (Memorial 
Sloan-Kettering Cancer Center, New York, NY, USA).  Mice were housed and bred in the 
Central Animal Facility at the University of Duisburg-Essen Medical College, Essen, 
Germany.  Mice were fed standard-type pellet food, water was available ad libitum, and 
the mice were housed in autoclaved cages.  The mice were monitored daily for any signs of 
illness or disease.  Mice were housed in a 12-hour light cycle.   
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2.3 Methods 
 
 
2.3.1 Methods in Molecular Biology 
 
2.3.1.1 DNA Techniques 
 
2.3.1.1.1    DNA Isolation from Mouse Tails 
 
For the isolation of DNA from mouse tails for purpose of genotyoing, app. 1-2 mm of 
mouse tail was cut and placed into 80 ul tissue lysis buffer containing Proteinase K. The 
samples were incubated at 56°C overnight and the volumes were raised to 800 μl with 
autoclaved ddH2O.  For PCR analysis, 1 μl of the lysate was used. 
 
 
2.3.1.1.2  Polymerase Chain Reaction 
 
For the identification of ASM wild-type, ASM heterozygotes (+/-) or ASM knock-out 
(-/-) mice the polymerase chain reaction was utilized.  For this reaction, 1 μl of the 
overnight tail digest (lysed in 80 μl lysis buffer and raised to 800 μl in ddH2O) was added 
to 1.2 μl 10x PCR buffer, 2.5 mM MgCl2, 1 μl dNTP mix (2.5 mM) and 10 pmol each of 
primers ASM-PA1-2, ASM-PA2-2 and ASM-PS-2 in a thin-walled 0.2-ml-PCR tube.  The 
temperature of the lid of the PCR Machine was raised to 104°C, and the temperature of the 
PCR block was raised to 96°C for 17 min, after which the follwing cycle was carried out 
35 times: 
 
Denaturation: 95°C for 1 min. 
Annealing:  58°C for 1 min. 
Elongation: 72°C for 1 min., 45 sec. 
 
After the last cycle the PCR block remained at 72°C for 5 minutes to complete elongation 
reactions, after which the samples were placed at 4°C.  5 μl of each sample was loaded 
onto an electrophoretic gel for genotype determination. 
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Cells in culture were regularly tested for the presence of contamination by 
mycoplasma.  For this, app. 1x105 B16F10 cells were counted and pelleted by 
centrifugation.  50 μl of tissue lysis buffer were added and the sample was incubated at 
56°C for app. 3 hours, after which the samples were boiled for 10 minutes.  The samples 
were diluted with 50 μl ddH2O, and for DNA quantification 10 μl of the sample was 
further diluted 1:50 with ddH2O and placed in a glass cuvette for measurement of 
absorption at 260 nm wavelength. 
 
For the polymerase chain reaction, 1 μl of the DNA was added to 2.5 μl 10x PCR 
buffer (Solis), 1.5 μl 25 mM MgCl2, 0.5 μl of 10mM dNTPs, 0.25 μl of both mycoplasma 
primers, and 1.25 U Taq polymerase (Solis).  The volume was raised to 25 μl with ddH2O 
in a 0.2 ml thin-walled PCR reaction tube.  The samples were heated to 96°C for 17 
minutes and the following cycle was repeated 25 times: 
 
Denaturation:  95°C for 1 minute 
Annealing:  60°C for 1 minute 
Elongation:  72°C for 1.5 minutes 
 
After the cycles were carried out, the PCR block remained at 72°C for a further 7 minutes 
to complete elongation.  The samples (15 μl of the reaction) were loaded onto a 1% 
agarose gel. 
 
 
2.3.1.1.3   Visualization of Amplified Products 
 
In order to determine the ASM genotype of mice, a 1% (w/v) electrophoretic agarose 
gel was poured in 1x TBE buffer that contained  20 μg ethidium bromide.  The PCR 
product samples (15 μl) were applied to the wells of the gel under 1x TBE along with a 
100-bp-standard, and a current of 5V/cm between anode and cathode was applied.  
Visualization of the DNA fragments took place by UV light at 302 nm wavelength due to 
the intercalation of Ethidium Bromide in the DNA. 
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2.3.1.2 Protein Techniques 
 
 
2.3.1.2.1   Production of Whole-Cell Lysates 
 
Thrombocytes were stimulated with B16F10 melanoma cells for indicated times and 
immediately lysed on ice with lysis buffer as described above.  The samples were boiled 
for 5 min in 1x SDS loading dye containing disulfide bond-denaturing 2-mercaptoethanol. 
 
 
2.3.1.2.2 Concentration Determination of Proteins 
 
To determine the amount and concentration of proteins in whole-cell lysates, 10 μl of 
the sample was analyzed spectrophotometrically at a wavelength of 595 nm.  Known 
amounts of BSA were analyzed simultaneously for production of a standard curve.  For 
analysis, proteins of either standard or unknown sample were placed in 1 ml of 
commercially available Bradford solution (BioRad). 
 
 
2.3.1.2.3   Separation of Proteins on SDS-PAGE 
 
Equal amounts of each sample were applied to the wells of 7.5%, 10% or 12% SDS 
PAGE gels.  The composition of the gels was as follows: 
 
Running gel: 7.5% SDS PAGE: 2.81 ml Solution A 
     5.0 ml Solution B 
     7.05 ml H2O 
     0.075 ml 20% SDS 
     0.03 ml N,N,N’,N'-Tetramethylenediamine, TEMED  
     0.03 ml 20% Ammonium persulfate, APS (BioRad)
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10% SDS-PAGE:   3.75 ml Solution A 
     5.0 ml Solution B 
     6.11 ml H2O 
     0.075 20% SDS 
     0.03 ml TEMED 
     0.03 ml 10% APS 
 
12% SDS-PAGE:   4.5 ml Solution A 
     5.0 ml Solution B  
     5.36 ml H2O 
     0.075 ml 20% SDS 
     0.03 ml TEMED 
  
    0.03 ml 10% APS 
 
Stacking Gel:    0.63 ml Solution A 
     0.21 ml Solution C 
     4.1 ml H2O 
     0.025 ml 20% SDS 
     0.02 ml TEMED 
     0.02 ml 10% APS 
 
The protein samples were applied to the gel and run at 25 V per gel through the 
stacking gel, after which the voltage was raised to 50V per gel as the proteins were carried 
through the separating gel.  A standard that contains a bromophenol blue dye was run 
along with the samples for later size identification.  Once the dye reached to bottom of the 
gel, the apparatus was dismantled and the gel was briefly soaked in transfer buffer.  The 
gel was placed upon a  nitrocellulose membrane (Hybond ECL), and the proteins were 
transferred onto the membrane in a BioRad Tank Blot Mini Protean II cassette.  After 
washing of the membrane with TBS-T and exposure to primary and secondary antibody, an 
X-Ray film (Amersham Biosciences) was exposed for various times to show protein bands. 
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2.3.1.2.4   Tyrosine- and Signaling Molecule Phosphorylation 
 
Platelets were stimulated by melanoma cells for the indicated stimulation times, lysed 
on ice and centrifuged at 15,000 rpm for 5 minutes to pellet nuclei and insoluble cellular 
debris.  Supernatants received 5 x reducing SDS sample buffer containing 250 mM Tris-
HCl pH 6.8, 20 % Glycine, 4 % SDS, 8 % 2-Mercaptoethanol and 0.2 % Bromophenol 
blue and were boiled for 5 minutes.  Samples were added to sodium dodecyl sulfate 
polyacrylamide gel (SDS-PAGE) ranging from 7-12 % and electrophoresed and blotted 
onto nitrocellulose membranes.  Membranes received 4 % BSA in Tris-buffered saline 
(TBS) for blocking for 1 h, washed in TBS supplemented with 0.1 % Tween (TBS-T) and 
exposed to 1 μg/ml monoclonal anti-phosphotyrosine 4G10 (UBI), anti- phospho-PLCγ 
(phospho-Tyr 1217, NEB), anti- phospho- MAP-K (phospho- Thr 202/ phospho- Tyr 204, 
NEB) or anti- phospho- JNK (phospho- Thr 183/ phospho- Tyr 185, NEB) antibodies for 4 
hours at room temperature or overnight at 4°C.  After exposure, the blots were extensively 
washed with TBS-T and subjected to alkaline phosphatase- coupled secondary antibodies 
at a concentration of 1:20,000 in 20 ml TBS-T for 60 minutes at room temperature.  After 
further extensive washing, the blots were developed using the Tropix chemilluminescence 
system after brief exposure of the blots to alkaline wash buffer (100 mM Tris-HCl, 100 
mM NaCl, pH 9.5) and exposed to X-Ray film.  
 
 
2.3.2 Cell Culture Techniques 
 
2.3.2.1 Passage of  Cell Cultures 
 
B16F10 malignant melanoma cells were cultured in MEM supplemented with 10% 
Fetal Bovine Serum, 10 mM HEPES pH 7.4, 2 mM L-Glutamine, 1 mM sodium pyruvate, 
100 μM non-essential amino acids, 100 units/ml penicillin and 100 ug/ml streptomycin (all 
from Gibco).  The cells were replaced by a freshly thawed and cultured aliquot after 21 
days of growth to avoid selection of specific clones.  Cells were grown to subconfluency 
prior to all experiments.  For passage, the cells were washed once in PBS and released 
from the T75 flask by addition of  0.5% Trypsin and incubation for 5 minutes at 37°C.  
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Trypsinization reaction was stopped by addition of  5 volumes supplemented MEM 
medium. 
 
 
2.3.2.2 Freezing and Thawing of Cells 
 
For long-term storage of cell lines the cells were centrifuged for 5 minutes at 250xg 
and resuspended in 1 ml freezing medium consisting of 70% supplemented medium, 20% 
FBS and 10% DMSO and transferred to a freezing vial (Nunc) and frozen at –80°C.  After 
24 hours the vials were placed into liquid nitrogen.  Thawing of cells occurred by 
placement of the vials into a 37°C water bath.  The cells were once washed in 10 ml of 
supplemented medium to get rid of DMSO, and placed into T75 flasks.   
 
 
2.3.2.3 B16F10 Melanoma Cell Purification 
 
Malignant melanoma cells (B16F10) were cultured in supplemented Mulbecco Eagle 
Medium (MEM) (see above).  Cells were grown to subconfluency and released from the 
T75 flask by use of 3 ml cell dissociation buffer (Invitrogen).  Melanoma cells were 
washed three times in 10 ml 1 M HEPES-Saline pH 7.4 (132 mM NaCl, 20 mM HEPES 
pH 7.4, 5 mM KCl, 1 mM CaCl2, 0.7 mM MgCl2, 0.8 mM MgSO4) with centrifugation 
steps at 250 x g for 5 minutes at room temperature.  The tumor cells were counted and 
resuspended in 20 μl 1x HEPES- Saline and equilibrated at 37°C for 8 minutes prior to use 
in stimulation experiments. 
 
 
2.3.3 Mouse Thrombocyte Isolation 
 
Mice were either bled retroorbitally or bled by a cut in the tail vein.  Approximately 
500 μl blood was obtained and immediately mixed with 3.8 % sodium citrate in a 1.5-ml- 
Eppendorff tube.  After dilution of the blood with 10 ml of 3.5 % Albumin (Sigma; 
Fraction V; fatty-acid free) the samples were incubated at 37°C for 15 minutes and 
centrifuged at 100 x g for 20 minutes without brake at room temperature.  The supernatants 
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were collected and re-centrifuged at 1340 x g for 15 minutes at room temperature to pellet 
thrombocytes.  The platelets were resuspended in Tyrode buffer (20 mM HEPES at pH 7.4, 
134 mM NaCl, 2.9 mM KCl, 12 mM NaHCO3, 0.34 mM Na2HPO4, 1 mM MgCl2 and 5 
mM glucose), counted and equilibrated at 37°C for 8 minutes before stimulation 
experiments. 
 
 
2.3.4 In Vivo Metastasis 
 
Malignant melanoma cells (B16F10) were released from T75 flasks by washing the 
cells in PBS and addition of 3 ml enzyme-free cell dissociation buffer (Gibco).  Cells were 
washed extensively and resuspended in 200 μl 1 x HEPES- Saline.  Mice were injected 
intravenously via the retrobulbar eye plexus with 100,000 melanoma cells.  After 21 days 
the mice were sacrificed and the visible metastases in the lung were counted.   
 
 
2.3.5 Interaction of Platelets with Tumor Cells 
 
2.3.5.1 Time Course Experimental Setup  
 
Tumor cells were released from T75 flasks by Cell Dissociation Buffer (Enzyme-free, 
PBS-based; Gibco) and washed extensively.  After resuspension in 1 x HEPES-Saline the 
cells were equilibrated at 37°C for 8 minutes and added to platelets at a ratio of 1 tumor 
cell per 100 platelets to initiate stimulation.  Platelets were allowed to be stimulated for 0 
sec (control), 15 sec., 30 sec. 45 sec., 60 sec., and 90 sec.  Termination of stimulation was 
achieved by addition of cell lysis buffer (25 mM HEPES pH 7.4, 0.1 % sodium dodecyl 
sulfate (SDS), 0.5 % sodium deoxycholate, 1 % Triton X-100, 100 mM NaCl, 10 mM NaF, 
10 mM Na2P2O7, 10 mM Na3VO4, 10 mM ethylene diamine tetraacetic acid (EDTA) and 
10 ug/ml aprotinin  and 10 ug/ml leupeptin) on ice for 5 minutes.  Control experiments 
were treated with equal volumes of HEPES-Saline. 
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2.3.5.2 Tyrosine- and Signaling Molecule Phosphorylation 
 
Platelets were stimulated by melanoma cells for the indicated stimulation times, lysed 
on ice and centrifuged at 15,000 rpm for 5 minutes to pellet nuclei and insoluble cellular 
debris.  Supernatants received 5 x reducing SDS sample buffer containing 250 mM Tris pH 
6.8, 20 % Glycine, 4 % SDS, 8 % 2-Mercaptoethanol and 0.2 % Bromphenol blue and 
were boiled for 5 minutes.  Samples were applied to sodium dodecyl sulfate 
polyacrylamide gel (SDS-PAGE) ranging from 7-12 % (for detection of Phosphotyrosine, 
a 12 % gel was used, as well as for detection of MAP kinase and JNK; detection of PLCγ 
required a 7 % gel) and and electrophorettically blotted onto nitrocellulose membranes.  
Membranes received 4 % BSA in Tris-buffered saline (TBS) for blocking for 1 h, washed 
in TBS supplemented with 0.1 % Tween (TBS-T) and exposed to 1 μg/ml monoclonal 
anti-phosphotyrosine 4G10 (UBI), anti- phospho-PLCγ (phospho-Tyr 1217, NEB), anti- 
phospho- MAP-K (phospho- Thr 202/ phospho- Tyr 204, NEB) or anti- phospho- JNK 
(phospho- Thr 183/ phospho- Tyr 185, NEB) antibodies for 4 hours at room temperature or 
overnight at 4°C.  After exposure, the blots were extensively washed with TBS-T and 
subjected to alkaline phosphatase- coupled secondary antibodies for 60 minutes at room 
temperature.  After further extensive washing, the blots were developed using the Tropix 
chemilluminescence system after brief exposure of the blots to alkaline wash buffer (100 
mM Tris-HCl, 100 mM NaCl, pH 9.5).  
 
 
2.3.6 Ceramide Release Assay 
 
After platelet stimulation by B16F10 tumor cells and cell lysis, the platelets were 
extracted with CHCl3:CH3OH:1N HCl (100:100:1; v/v/v).  The organic phase was obtained 
and dried using a speedvac.  Diacylglycerol was degraded in 0.1 N methanolic KOH at 
37°C for 60 minutes.  After re-extraction the organic phase was dried and resuspended in 
20 μl of a detergent solution (7.5 % (w/v) n-octylglucopyranoside, 5 mM cardiolipin, 1 
mM diethylenetriaminepentaacedic acid, DETAPAC).  Formation of micelles was initiated 
by bath sonication for 10 minutes.  A phosphorylation buffer (0.1 M imidazole/HCl pH 
6.6, 0.1 M NaCl, 25 mM MgCl2, 2 mM EGTA, 2.8 mM dithiothreitol (DTT), 1 μM 
adenosine triphosphate (ATP), 10 μCi [32P]-γ ATP and 0.024 units/sample DAG kinase) 
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initiated ceramide phosphorylation, and the samples were incubated at room temperature 
for 30 minutes.  Termination of the reaction was achieved by addition of 1 ml 
CHCl3:CH3OH:1N HCl (100:100:1; v/v/v), 170 μl buffered saline solution (135 mM NaCl, 
1.5 mM CaCl2, 0.5 mM MgCl2, 5.6 mM Glucose, 10 mM HEPES pH 7.2) and 30 μl of a 
100 mM EDTA solution.  The resulting upper phase was removed, and the lower organic 
phase was again concentrated by SpeedVac centrifugation. The dried lipids were dissolved 
in 20 µl/sample CHCl3:CH3OH (1:1 v/v).  Lipids were separated on a Silica G60 TLC 
plate. A solvent system of CHCl3:CH3OH:CH3COOH (65:15:5 v/v), was added to the TLC 
chamber, and was allowed to saturate the atmosphere for 1 h by using a sheet of Whatman 
filter paper. The silica plates were loaded with the solubilized lipids, placed into the TLC 
chamber and the solvent front was allowed to migrate to the top of the plate. The plate was 
then removed, air dried for 45 min and exposed to X-ray films for 24-72 hrs. Ceramide-
spots were identified by co-migration with a C16-ceramide-1-phosphate standard, scraped 
from the plate into 20 ml polyethylene vials and quantified by liquid scintillation counting 
using the Cerenkov protocol. 
 
 
2.3.7 Acid Sphingomyelinase Assay 
 
After stimulation of platelets with B16F10 melanoma cells, the cells were lysed with 
250 mM sodium acetate pH 5.0, 1.3 mM EDTA and 1% NP-40.  After three sonication 
steps for 10 seconds each, the samples were incubated for 30 minutes at 37°C with [14C]-
Sphingomyelin (0.05 μCi/sample, corresponding to 52 mCi/mmol; MP-Biomedicals) that 
was resuspended in 250 mM sodium acetate pH 5.0, 1.3 mM EDTA and 0.1% NP-40 after 
drying.  Termination of the sphingomyelinase reaction was achieved by extraction in 8 vol 
of CHCl3:CH3OH (2:1, v/v).  The phases were separated by centrifugation and the upper 
phase was placed into liquid scintillation fluid for radioactive scintillation counting.  As 
measurement for the activity of the enzyme, hydrolysis of [14C]-Sphingomyelin by the acid 
spingomyelinase results in the formation of water-soluble [14C]-Choline chloride that is 
extracted in the upper phase.  [14C]-Sphingomyelin was first dried by SpeedVac 
centrifugation and solubilized into micelles in ASM-lysis buffer, using a bath sonicator for 
10 min. Lipids were extracted by addition of 1 ml/sample chloroform:methanol (2:1, v/v), 
followed by vigorous vortexing for 30 sec and centrifugation at 800 x g for 10 min. This 
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results in separation of phosphorylcholine in the upper (aqueous) phase and ceramide in 
the lower (organic) phase. An aliquot (350 µl) of the upper phase was carefully collected 
and transferred in 20 ml polyethylene vials filled with 3.5 ml Scintillation Cocktail, 
followed by quantification by liquid scintillation counting. 
 
  
2.3.8 Fucoidan Experiments 
 
2.3.8.1 Fucoidan Preparation and Mouse Injection 
 
Fucoidan stock was prepared at a concentration of 10 mg/ml in HEPES-Saline pH 7.4 
and sterile-filtered.  Unused aliquots were frozen at –20°C.  For injection, fucoidan was 
diluted in HEPES-Saline.  Mice were injected buffer only as control (HEPES-Saline), 
0.025 μg, 0.1 μg, 0.4 μg and 2 μg in a total volume of 200 μl.  Injection occurred through 
the tail vein or the retrobulbar complex. 
 
 
2.3.8.2 B16F10 Mouse Injection 
 
B16F10 melanoma cells were released from T75 flasks and purified as described 
above.  The cells were resuspended in 200 μl HEPES-Saline to yield 100,000 cells per 
injection.  Mice were injected via the retrobulbar eye complex  approximately 2 hours after 
fucoidan injection.  Control mice received 200 μl HEPES-Saline only. 
 
 
2.3.8.3 Mouse sacrifice and lung metastasis determination 
 
21 days after fucoidan and B16F10 melanoma cell injection, the mice were sacrificed by 
cervical dislocation and the lungs removed.  Visible metastases were counted and recorded. 
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2.3.8.4  FACS Analysis of Platelet Degranulation and P-selectin Expression 
 
Mouse thrombocytes were isolated as described above (see 2.3.3).  B16F10 melanoma 
cells were released from T75 flasks by Cell Dissociation Buffer (Enzyme-free, PBS-based; 
Gibco), washed extensively in HEPES-Saline, and allowed to remain at 37oC.  After 
resuspension in 1 x HEPES-Saline the thrombocytes were equilibrated at 37°C for 5 
minutes and added to 2 mg/ml fucoidan in HEPES-Saline.  After a further 3 minutes at 
37oC tumor cells were added to the platelet:fucoidan mix at a ratio of 1 tumor cell per 100 
platelets to initiate stimulation.  Anti-P-selectin antibody was added immediately at a 
concentration according to the manufacturer’s protocol (Emfret), and the reactions were 
allowed to remain at room temperature for 15 minutes.  The volume was raised to 500 μl 
with phosphate-buffered saline (PBS; without Mg2+, Ca2+).  FACS analysis was performed. 
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3.  Results 
 
 
3.1 Metastasis of Melanoma Cells in Acid Sphingomyelinase-Deficient and 
Wild-Type Mice   
 
3.1.1 Acid sphingomyelinase deficiency attenuates B16F10 melanoma metastasis 
 
Acid Sphingomyelinase-positive and -deficient mice were injected intravenously with 
1 x 105 B16F10 melanoma cells in order to investigate the function of sphingolipids and 
acid sphingomyelinase for platelet-mediated tumor metastasis.  After 21 days these mice 
were sacrificed by cervical dislocation, the lungs were removed, and the number of visible 
lung metastases was determined.  Results revealed a vast difference between 
hematogenous tumor cell metastasis in wild type mice with 54 ± 5 pulmonary metastases 
compared to acid sphingomyelinase-deficient mice with 1.8 ± 1.9 pulmonary metastases, 
indicating a reduction of pulmonary B16F10 melanoma cell metasases of 97% in the lungs 
of acid sphingomyelinase-deficient mice.  These data depicted in Fig. 5 A and 5 B suggest 
a pivotal role of the acid sphingomyelinase for the metastasis of B16F10 melanoma cells to 
the lung.  
 
 
 
*
Fig. 5 A: 
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Fig. 5 A + B: Metastasis of melanoma cells is prevented in acid sphingomyelinase-
deficient mice 
 
Acid sphingomyelinase-positive and -deficient mice were intravenously injected with 5x104 B16F10 
melanoma cells, and the number of lung metastases was determined after 21 days. Deficiency of acid 
sphingomyelinase prevented metastasis of B16F10 tumor cells into the lung, which occurred at multiple sites 
in wild-type mice. Panel A shows the mean ± SD of the number of pulmonary B16F10 metastases in 9 wild-
type and 8 acid sphingomyelinase-deficient mice, respectively. Significant differences (p≤ 0.05, t-test) 
between ASM-positive and ASM-deficient cells are indicated by an asterisk*.  Panel B displays the lungs of 
a typical experiment. The dark spots in the lung tissue on the left-side panel are the melanoma metastases 
(arrows) that are absent in the lungs on the right-hand panel. 
 
 
 
3.2  Interaction of Platelets with B16F10 melanoma cells 
 
3.2.1  Tumor cells induce activation of acid sphingomyelinase in platelets 
 
In order to determine whether the interaction of platelets with B16F10 tumor cells 
causes stimulation of the acid sphingomyelinase, platelets of wild-type and acid 
sphingomyelinase-deficient mice were purified and co-incubated with B16F10 tumor cells 
and the activity of the acid sphingomyelinase was determined.  Results (n=4) show a rapid 
stimulation of the acid sphingomyelinase upon co-incubation of wild-type platelets with 
Fig. 5 B: 
              ASM +/+ ASM -/- 
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tumor cells, as shown in Fig. 6 A.  Acid sphingomyelinase activity increased within 5 
seconds of co-incubation with tumor cells, peaked at 10 seconds and declined to baseline 
within 45 seconds.  When platelets of acid sphingomyelinase-deficient mice were co-
incubated with tumor cells, no increase of acid sphingomyelinase activity was observed 
(Fig. 6 B), indicating that tumor-platelet interaction results in an exclusive activation of the 
platelet acid sphingomyelinase, while the enzyme acid sphingomyelinase present in the 
B16F10 tumor cells  does not seem to be activated upon contact with platelets.   
 
Fig. 6 A: 
*
*
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Fig. 6 A+B: Tumor cells induce activation of acid sphingomyelinase in platelets.   
 
(A and B) Incubation of wild-type platelets with B16F10 tumor cells induced a rapid, transient activation of 
acid sphingomyelinase (ASM). No changes of the enzyme’s activity were observed upon co-incubation of 
acid sphingomyelinase-deficient platelets with tumor cells indicating an activation of the platelet acid 
sphingomyelinase, while the activity of the enzyme in tumor cells seems to be unaffected. Panel A displays 
the activity of the acid sphingomyelinase in wildtype platelets after subtraction of the acid sphingomyelinase 
activity in tumor cells. Significant differences (p≤ 0.05, t-test) between ASM activity of stimulated vs. 
unstimulated cells are indicated by an asterisk*.  Panel B demonstrates the total acid sphingomyelinase-
activity after co-incubation of B16F10 cells with platelets. Total activity of the unstimulated samples was 
achieved by addition of the activity in untreated platelets and tumor cells. Platelets were purified from wild-
type and acid sphingomyelinase-deficient mice, stimulated with tumor cells (105 tumor cells/107 platelets), 
lysed and the acid sphingomyelinase activity was determined by the consumption of [14C]-sphingomyelin 
added to the lysates. Displayed is the mean ± SD of 4 independent experiments. Significant differences (p≤ 
0.05, t-test) between stimulated and unstimulated samples are indicated by an asterisk*.   
 
 
 
3.2.2  Tumor cells induce the release of ceramide from platelets 
 
Since acid sphingmyelinase hydrolyzes sphingomyelin to form ceramide, stimulation 
of acid sphingomyelinase in platelets isolated from wild-type mice with B16F10 tumor 
cells resulted in a release of ceramide, while purified platelets isolated from acid 
sphingomyelinase-deficient mice failed to release ceramide upon stimulation with B16F10 
Fig. 6 B: 
*
*
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melanoma cells.  These data shown in Fig. 7 indicate that acid sphingomyelinase in 
platelets and not in the tumor cells mediated the release of ceramide upon co-stimulation of 
the cells. 
 
 
 
Fig. 7:  Ceramide is rapidly released upon co-incubation of wild-type platelets with 
B16F10 tumor cells.  
 
When platelets were co-incubated with B16F10 melanoma cells, release of ceramide was observed within 10 
seconds of co-incubation, while no release of ceramide was observed in acid sphingomyelinase-deficient 
platelets stimulated with the tumor cells. Platelets were purified from wild-type and acid sphingomyelinase-
deficient mice, co-incubated with tumor cells as above and ceramide release was determined by the DAG-
kinase assay. Ceramide in tumor cells was subtracted from the total amount of ceramide in the samples to 
calculate the formation of ceramide in the platelets. Displayed are the means ± SD of 3 independent 
experiments.   
Significant differences (p≤ 0.05, t-test) between stimulated and unstimulated samples or between ASM-
positive and ASM-deficient cells are indicated by an asterisk* or a delta Δ, respectively. 
 
 
 
 
 
 
 
 
Fig. 7  
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3.3  Role of P-selectin in Acid Sphingomyelinase Activation 
 
3.3.1 Deficiency of P-selectin prevents Acid Sphingomyelinase Activation 
 
The adhesion receptor P-selectin is known to be involved in the interaction of platelets 
with tumor cells.  When platelets derived from P-selectin-deficient mice and normal mice 
were co-incubated with B16F10 melanoma cells, the deficiency of P-selectin in platelets 
prevented activation of acid sphingomyelinase and subsequent release of ceramide, while 
these events rapidly occurred in platelets obtained from wild-type mice (Fig. 8). 
 
 
 
Fig. 8: P-selectin mediates activation of acid sphingomyelinase in platelets upon co-
incubation with B16F10 melanoma cells 
 
B16F10 melanoma cells rapidly stimulated acid sphingomyelinase (ASM) in P-selectin-positive platelets, 
while no activation of the enzyme was observed in P-selectin-deficient platelets upon co-incubation with 
tumor cells. Platelets from normal or P-selectin-deficient mice were purified, incubated with B16F10 tumor 
cells and the activity of acid sphingomyelinase was determined by consumption of [14C]-sphingomyelin. The 
results are the mean ± SD of 4 independent studies.   
Significant differences (p≤ 0.05, t-test) between stimulated and unstimulated samples or between P-selectin-
positive and P-selectin-deficient cells are indicated by an asterisk* or a delta Δ, respectively. 
Fig. 8: 
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3.3.2  P-selectin-deficient platelets fail to release ceramide 
 
Wild-type platelets and platelets obtained from P-selectin-deficient mice were co-
incubated with B16F10 melanoma cells, and subsequently the amount of ceramide released 
was measured in a DAG kinase assay.  While wild-type platelets released ceramide upon 
co- incubation, platelets that did not express P-selectin showed no release of ceramide (Fig. 
9). In wild-type platelets, the amount of ceramide released peaked after about 15 seconds 
and declined back to baseline within 60 seconds, while in P-selectin-deficient platelets the 
amount of ceramide released maintained baseline level.  
 
 
Fig. 9: P-selectin mediates release of ceramide in platelets upon co-incubation with 
B16F10 melanoma cells 
 
Incubation of P-selectin-positive platelets with B16F10 tumor cells triggered the release of ceramide within 
10 seconds, as determined by the DAG-kinase assay. P-selectin-negative platelets failed to release ceramide 
upon stimulation with B16F10 tumor cells. Ceramide concentrations in the tumor cells were subtracted from 
the total values. Shown is the mean ± SD of 3 independent experiments.   
Significant differences (p≤ 0.05, t-test) between stimulated and unstimulated samples or between P-selectin-
positive and P-selectin-deficient cells are indicated by an asterisk* or a delta Δ, respectively. 
 
Fig. 9: 
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3.3.3  Intracellular Molecule and Tyrosine-Phosphorylation 
 
Failure of P-selectin-deficient platelets to activate acid sphingomyelinase after co- 
stimulation with B16F10 melanoma cells was not caused by a reduced interaction of 
platelets with tumor cells, because other signaling events elicited by tumor cells in platelets 
were not affected, as is shown by western blotting in Fig. 10 A-D.  Experiments revealed a 
very similar induction of cellular tyrosine phosphorylation (Fig. 10 A) and phosphorylation  
of p44/42 mitogen-activated protein kinase (MAP-K, Fig. 10 B), c-Jun N-terminal kinase 
(JNK, Fig. 10 C) or phospholipase Cγ (Fig. 10 D) in P-selectin-positive and -negative 
platelets when co-stimulated with B16F10 melanoma cells.  These enzymes are typical 
markers of cellular activation and represent major signaling pathways in many cells, 
leading to reorganization of the cytoskeleton, calcium increase or PKC activation, for 
example. 
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Fig 10 A-D:  P- Selectin deficiency does not affect some signaling events in platelet-
tumor cell interaction.   
 
Incubation of platelets with B16F10 melanoma cells induced tyrosine phosphorylation of several intracellular 
molecules (A) and phosphorylation of PLCγ (B), MAP-K (C) and JNK (D) on residues that indicate 
activation of these molecules. However, deficiency of P-selectin in platelets did not significantly alter these 
events, indicating that B16F10 tumor cells are also able to activate platelets via pathways that are 
independent of P-selectin. Protein phosphorylation was determined by western blotting of whole cell lysates 
and detection with anti-phosphotyrosine, anti-phospho-PLCγ, anti-phospho-MAP-K or anti-phospho-JNK 
antibodies and development using the Tropix® chemiluminescence system. 
 
Fig. 10 A: 
Fig. 10 B: 
Fig. 10 C: 
Fig. 10 D: 
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3.3.4  P-selectin mediates B16F10 Tumor Cell Metastasis 
 
To determine hematogenous metastasis of B16F10 melanoma cells, P-selectin-positive 
and -negative C57/Bl6 mice were intravenously injected with 1x105 B16F10 tumor cells.  
After 21 days the mice were sacrificed, the lungs removed, and the number of metastases 
was determined.  The results depicted in Fig. 11 reveal multiple pulmonary metastases in 
wild- type mice that were reduced by 94% in P-selectin-deficient mice. 
 
 
 
 
 
 
Fig. 11: P-selectin mediates B16F10 tumor cell metastasis 
 
Metastasis of B16F10 tumor cells was prevented in P-selectin-deficient mice, while wild-type mice showed 
multiple tumor metastases in the lung. The figure demonstrates the quantitative analysis of B16F10 
metastases in the lung and displays the mean ± SD of melanoma in the lungs 21 days after intravenous 
injection of 50,000 B16F10 melanoma cells into P-selectin-positive or -deficient syngenic C57/Bl6 mice. 
Represented are the mean ± SD from 11 wild-type and 10 P-selectin-deficient mice. 
 
 
 
Fig. 11: 
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3.3.5  Co-incubation of platelets with B16F10 melanoma cells leads to P-selectin and 
GPIIbIIIα translocation independently of the acid sphingomyelinase 
 
To determine the significance of the acid sphingomyelinase in the degranulation and 
translocation of P-selectin and the platelet-specific glycoprotein GPIIbIIIα in platelets, 
1x106 platelets of both wild-type and acid sphingomyelinase-deficient mice were co- 
incubated with 1x105 B16F10 melanoma cells.  For FACS analysis, the FITC- labeled 
antibody α-P-selectin and the PE-labeled antibody α-GPIIbIIIα were used.  Results 
showed that degranulation occurred in wild-type platelets and P-selectin and GPIIbIIIα 
were translocated to the outer cellular membrane (Fig. 12, left panel). These events were 
not altered by deficiency of the acid sphingomyelinase in platelets (Fig. 12, right panel), 
indicating that the process of degranulation and translocation of the P-selectin molecule 
and the GPIIbIIIα molecule occurs independently of the presence of acid 
sphingomyelinase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
  47 
Fig. 12: 
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Fig. 12: Platelet degranulation and P-selectin/GPIIbIIIa expression after stimulation 
with B16F10 melanoma cells occurs in wild-type and ASM-deficient Platelets. 
 
1x106 Platelets were obtained from either wild-type or acid sphingomyelinase-deficient C57/Bl6 mice and 
stimulated with 1x105 B16F10 melanoma cells. The antibodies for P-selectin and GPIIbIIIα were added to 
the samples and FACS analysis was carried out.  The left panel (indicating wild-type platelets used) shows 
degranulation and a decrease in size of the platelets and expression of P-selectin and GPIIbIIIα. Acid 
sphingomyelinase-deficient platelets (right panel) did not significantly differ from wild-type platelets, 
suggesting that degranulation and P-selectin and GPIIbIIIα expression occurs independently of the presence 
of the acid sphingomyelinase. 
 
 
3.4 Fucoidan and Tumor Metastasis 
 
3.4.1 Fucoidan prevents B16F10 tumor metastasis in mice 
 
Wild-type mice were injected with various amounts of fucoidan, and after one hour 
were injected with B16F10 melanoma cells.  Upon sacrifice of the mice after two weeks 
and removal of the lungs, the number of metastases was determined.  Results (Fig. 13 
A+B) revealed that while the control mice (injection of HEPES-Saline instead of fucoidan) 
exhibited high numbers of metastases in the lung (mean=48 ± 18), there is a gradual 
decrease in the number of pulmonary metastases.  When 0.08 mg/mouse fucoidan was 
administered, the mice exhibited a mean number of 23 ± 10 metastases in the lung.  This 
number was further reduced by the administration of 0.4 mg/mouse fucoidan to a mean of 
5 ± 3 tumor metastases, and when 2.0 mg/mouse fucoidan was injected,  metastasis was 
prevented. 
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Fig. 13 A: 
 
Fig. 13 B: 
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Fig. 13 A+B : Injection of fucoidan prevents B16F10 melanoma cell metastasis. 
 
Intravenous injection of 2 mg/mouse of fucoidan 2 hours prior to intravenous injection of  1 x 105 B16F10 
melanoma cells abolished tumor metastasis to the lung of C57/Bl6 mice (n=3 per condition).  Mice were 
sacrificed by cervical dislocation 21 days after melanoma cell/fucoidan treatment, the lungs were removed 
and the visible metastases were counted.  Panel A shows the results of a typical experiment (metastases at 
arrowheads).  Panel B indicates the mean ± SD of three independent experiments. 
Significant differences (p≤ 0.05, t-test) between fucoidan-treated and -untreated samples are indicated by an 
asterisk*. 
 
 
 
3.4.2  FACS analysis of tumor cell-platelet interaction after treatment with 
fucoidan 
 
When wild-type platelets or platelets from acid sphingomyelinase-deficient mice were 
co-incubated weith B16F10 melanoma cells in the presence of various amounts of 
fucoidan, FACS analysis revealed that when stained for P-selectin with P-selectin 
antibody, 2 mg/ml fucoidan was sufficient to block the interaction of platelets with B16F10 
tumor cells (Fig. 14).  While wild-type platelets co-incubated with tumor cells showed that 
platelets rapidly degranulated to translocate P-selectin to the cellular surface, this 
degranulation was abolished by the treatment of fucoidan and the platelets remained 
unactivated.  
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Fig. 14: 
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Fig. 14:  Fucoidan prevents activation through B16F10 co-incubation of 
thrombocytes. 
 
While co-incubation of wild-type thrombocytes with HEPES-saline caused no effect in thrombocytes (top 
panel, left), co-incubation of 1 x106 wild-type thrombocytes with 1 x105 B16F10 melanoma cells rapidly 
activates thrombocytes to degranulate and expose P-selectin molecule to the outer surface of the cell (top 
panel, right), as detected by α-P-selectin antibody.  When 2.0 μg/mouse fucoidan was added to the 
thrombocytes prior to B16F10 melanoma cell addition, no activation or degranulation of the thrombocytes 
was detected by α-P-selectin antibody (bottom panel, left).   P-selectin-deficient thrombocytes, when co-
incubated with B16F10 melanoma cells in the absence of fucoidan, were still activated and degranulated 
(bottom panel, right), indicating the lack of P-selectin itself does not prevent activation of thrombocytes by 
B16F10 melanoma cells.  These findings are represented in the bottom graphical analysis.  
 
 
 
 
3.5 Transplantation of Wild-Type Bone Marrow reconstitutes B16F10 
Tumor Metastasis in P-selectin-Deficient Mice 
 
 
To discriminate whether P-selectin in platelets or endothelial cells mediates B166F10 
metastasis, P-selectin wild-type and P-selectin-deficient mice were irradiated and 
transplanted with bone marrow from P-selectin wild-type or P-selectin-deficient mice,  
sacrificed after 21 days, the lungs were removed, and visible metastases were counted. 
Deletion of P-selectin in thrombocytes, i.e. wild-type mice transplanted with P-selectin-
deficient bone marrow, abolished tumor metastasis of intravenously injected tumor cells, 
while deficiency of P-selectin in endothelial cells, i.e. P-selectin-deficient mice 
transplanted with wild-type bone marrow, did not significantly influence tumor metastasis 
(Fig. 15).  Injection of P-selectin wild-type bone marrow in P-selectin-/- mice reconstituted 
tumor metastasis. These results  indicate that thrombocytic P-selectin plays a significant 
role in tumor metastasis of B16F10 melanoma cells in the lungs of mice, while endothelial 
P-selectin expression is of less importance. 
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Fig. 15: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15:  Transplantation of wild-type bone marrow in P-selectin-deficient mice 
reconstitutes B16F10 melanoma cell metastasis.   
 
Wild-type or P-selectin-deficient mice were irradiated and transplanted with P-selectin-deficient or wild-type 
bone marrow.  This resulted in mice having P-selectin-deficient thrombocytes and normal endothelial cells, 
or wild-type thrombocytes and P-selectin-deficient enothelial cells.  These mice, as well as non-transplanted, 
P-selectin-deficient, and wild-type mice, were injected intravenously with 5x104 B16F10 melanoma cells, 
and the number of visible pulmonary metastases was determined after 21 days.  The graph shows the mean ±  
SD of pulmonary metastases of three mice per experiment.  
Significant differences (p≤ 0.05, t-test) between wildtype mice transplanted or not with P-selectin-deficient 
bone marrow are indicated by an asterisk*, while differences between P-selectin-deficient mice transplanted 
or not with wildtype bone marrow are indicated by a delta Δ. 
 
Δ *
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4.  Discussion 
 
 
4.1  Discussion of the Methods 
 
4.1.1  DAG-kinase assay for ceramide measurement 
 
The importance of the development of rapid and quantitative assays for the measurement 
of ceramide levels is revealed in the crucial role of ceramide in several cellular processes 
and stress responses in particular.  Methods that have been developed for the 
quantification of ceramide include normal phase HPLC analysis after derivatization with a 
fluorescent tag (Iwaromi et al. 1979; Previati et al. 1996; Couch et al. 1997; Yano et al. 
1998) and cellular labeling with radioactive precursor (Tepper et al., 2000).  The liberated 
and derivatized sphingoid bases can be used after ceramide is being hydrolyzed via HPLC 
(Smith et al., 1995) and fatty acids by means of gas chromatography/mass spectrometry 
(Samuelsson et al., 1970).   
 
The diacylglyceride (DAG or DG) assay has emerged to become the most common 
method for ceramide quantification with the advantages of the assay being the 
measurement of total mass levels of ceramide, usage of crude lipid extracts, and the ability 
that a large number of samples can be processed in a rapid manner.  Hokin and Hokin 
originally reported the DAG activity (Hokin and Hokin, 1959), showing the linear 
relationship between the amount of diglyceride added to an in vitro assay and the amount 
of phosphatidic acid formed (Kennerly et al., 1979).  Structurally, ceramides share 
similarities with diglycerides, and it was shown that bacterial DAG kinase can utilize 
ceramide as a substrate nearly five times greater than that for diglycerides (Schneider and 
Kennedy, 1973).  Modifications of the assay demonstrated that DAG kinase could also be 
used for quantitative conversion of ceramide-1-phosphate. 
 
Ceramide is a nonpolar molecule; therefore, there is a need that it be extracted from cells 
after cell lysis in organic solvents like chloroform and methanol.  Acidifying the lysate by 
the addition of hydrochloric acid aids in the extraction of shorter acyl chain ceramide-1-
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phosphates or hydroxylated ceramides.  In the DAG kinase reaction, it is cucial that the 
substrate be presented to the enzyme in a soluble form for the most effective conversion to 
product.  To this end, mixed micelles that contain a non-ionic detergent like n-octyl-β-D-
glycopyranoside and a phospholipid like cardiolipin are being used.  The level of  
ceramide conversion to ceramide-1-phosphate is of particular importance in this assay 
since the extraction must complete with a total conversion of DAG and ceramide; 
otherwise, the results will be influenced by the effects of efficiency of the reaction and to 
possible exclusion between DAG and ceramide substrates. The phosphorylated substrates 
DAG and ceramide are easily separated via thin layer chromatography. 
 
 
4.1.2  Acid sphingomyelinase activity determination 
 
The determination of acid sphingomyelinase enzyme activity in cell lysates requires 
sphingomyelin labeling by radioactivity or fluorescence.  In this study, the enzymatic 
activity was measured by the degradation of radioactive [14C]-sphingomyelin to ceramide 
and phosphorylcholine.  The radioactive label is attached to the choline group and is 
soluble in water, the radioactivity that is released can be separated from the substrate 
because the latter partitions to the organic phase after extraction.  By performing the assay 
in this study at a pH of 5.0, acid sphingomyelinase activity was discriminated from neutral 
and basic sphingomyelinases, which also utilize the substrate sphingomyelin. Because of 
the difficulty in bringing together the enzyme and substrate molecules in the presence of 
cell homogenates, a suitable detergent, such as Triton X-100 was used. It should be noted 
that, apart from emulsifying the substrate, the detergents bind and modify the enzyme 
activity, thus detergent concentration and initial detergent:substrate ratio was kept 
constant for reproducibility of assays. Finally, it has been suggested that the ASM may be 
located in detergent-resistant/insoluble fractions; thus, for determination of ASM activity 
in whole-cell lysates, no centrifugation step was performed after lysis and sonication of 
the cells to prevent pelleting and loss of the ASM. 
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4.1.3  Transgenic Animals 
 
4.1.3.1  Acid sphingomyelinase-deficient mice 
 
To determine the role and importance of acid sphingomyelinase in melanoma cell 
metastasis, thrombocytes obtained from acid sphingomyelinase-deficient mice were 
obtained.  The acid sphinomyelinase knock-out mice were originally generated in the 
laboratory of Dr. Edward Schuchman (Mount Sinai School of Medicine, New York, NY, 
USA).  These mice have been a valuable tool in the investigation of the role of the acid 
sphingomyelinase enzyme role in several different cellular processes.  It was shown that 
acid sphingomyelinase-deficient mice generated by gene targeting abundantly store 
sphingomyelin in the reticuloendothelial system of liver, spleen, bone marrow, and in 
brain (Nix et al., 2000). Liver cells of acid sphingomyelinase-deficient mice accumulate 
sphingomyelin and glycosphingolipids in purified lipid bilayers of microsomes, Golgi, 
and the plasma membrane, but cholesterol is depleted in the plasma membrane.  Studies 
from Lozano and Kolesnick pointed out that mice displayed only a minimal increase in 
sphingomyelin content up to an age of 12-16 weeks, and unchanged levels of caveolin-1, 
normal MAP-kinase signaling, normal tyrosine phosphorylation patterns, absence of 
lymphopenia, normal T-cells and no decrease in FLIP levels (Lozano et al., 2001) 
suggesting that these mice are a suitable model for studying the function of the ASM.  
 
Hence, all experiments involving these mice were carried out with animals younger than 
12 weeks of age to permit analysis of acid sphingomyelinase function of the effects of 
sphingomyelin accumulation. 
 
 
4.1.3.2   P-selectin-deficient mice 
 
In this study the P-selectin-deficient mice were obtained from Jackson laboratories.  P-
selectin is suggested to act by controlling the adhesion of tumor cells to vascular 
endothelial cells.  Since tumor cell-induced activation of platelets is considered a crucial 
step in tumor metastasis, it is assumed that a mechanism for tumor metastasis might be the 
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stimulation of expression of platelet P-selectin (Krause and Turner, 1999), leading to the 
formation of tumor cell:platelet aggregates that could form emboli in small vessels or 
adhere to endothelial cells and initiate metastatic deposition (Krause and Turner, 1999).  It 
was, however, determinded by Hakomori et al. (Hakomori, 1996) that tumor cells that 
were able to activate platelets were not capable of binding to P-selectin, yet Stone and 
Wagner (1993) could show the P-selectin-dependent binding of platelets to two small lung 
tumor and two neuroblastoma cell lines.  Interestingly, it was shown (Kates and Geng, 
1998) that activated platelets increased adhesion of melanoma cells to endothelial cells 
under flow conditions which was mainly due to platelet GPIIb/IIIα.  P-selectin-deficient 
mice that were subcutaneously implanted with tumor cells showed significantly slower 
tumor growth (Kim et al., 1998), and fewer lung metastases were observed with 
intravenously injected tumor cells.  These studies also showed that platelets from the P-
selectin-deficient mice failed to adhere to tumor cell surface mucins and the lungs 
exhibited significantly fewer platelet clumps.  Interestingly, Nooijen et al.  (1998) 
observed that P-selectin is absent from the microvasculature in advanced primary 
melanoma and melanoma metastasis as compared to benign melanoma and normal skin, 
suggesting that advanced melanoma may evade inflammatory regression by decreased 
endothelial P-selectin expression.    
 
 
4.2  Discussion of the Results 
 
 
4.2.1  Acid sphingomyelinase deficiency attenuates tumor metastasis 
 
Hematogenous metastasis occurs when tumor cells enter the blood stream, interact with 
host blood cells, avoid host defense system, arrest on the endothelial cells in the blood 
stream, extravasate and colonize a distant tissue.  Evidence indicates that hematogenously 
disseminating tumor cells interact with platelets and leukocytes, forming microemboli that 
facilitate their arrest in the vasculature (Karpatkin and Pearlstein, 1981; Gasic, 1984; 
Fidler, 1990; Honn et al., 1992).  A prominent feature of tumor cells is an altered cell 
surface glycosylation (Fukuda, 1996; Hakomori, 1996; Kim et al., 1996; Kannagi, 1997; 
Kim and Varki, 1997); in particular, sialylated fucosylated glycan expression like sialyl- 
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Lewis-x and sialyl-Lewis-a correlate with poor prognosis due to tumor progression and 
high rate of tumor metastasis.  Certain sialyl Lewis- x/a glycans found on leukocytes and 
endothelium are recognized by vascular cell adhesion molecules such as selectins 
(Fukuda, 1996,  Takada et al. 1993), mediating tumor cell interaction with platelets, 
leukocytes and endothelial cells (Varki and Varki, 2002; Mannori et al., 1995; Kim et al., 
1999; Izumi et al., 1995).  Platelets adhere to some human carcinoma cells mostly via P-
selectin and inhibition of this interaction leads to attenuation of metastasis in vivo (Kim et 
al., 1998; Borsig et al., 2001).  Additionally, platelet adhesion to tumor cells physically 
interferes with access of leukocytes to tumor cells, suggesting a possible shielding effect 
(Nieswandt et al., 1999; Borsig et al., 2001). 
 
In this present study it was shown that acid sphingomyelinase-deficient C57/Bl6 mice 
showed a significantly reduced number of metastases in the lung after 21 days of injection 
of B16F10 melanoma cells as compared to wild type C57/Bl6 mice (Figure 1 A+B), 
therefore suggesting a pivotal role of the acid sphingomyelinase enzyme in the process of 
tumor metastasis of melanoma cells.  A possible role of acid sphingomyelinase in tumor 
metastasis has not previously been shown, and signaling events elicited by tumor cells in 
platelets are not characterized.  It has been previously shown that the acid 
sphingomyelinase is very rapidly activated by a number of stress and pro-apoptotic stimuli 
to release ceramide that forms large ceramide-enriched membrane platforms and therefore 
reorganize the cellular membrane to facilitate signaling into the cell.  Several pro-
apoptotic receptor molecules like CD95 (Cifone et al., 1994; Gulbins et al., 1995; Brenner 
et al., 1998), TNF-R (Schutze et al., 1992) or IL-1 (Mathias et al., 1993), amongst others, 
have been demonstrated to activate the acid sphingomyelinase and to result in a release of 
ceramide.  Genetic experiments on acid sphingomyelinase-deficient mice have shown the 
important role of acid sphingomyelinase for induction of apoptosis by these stimuli 
(Gulbins, 2002).   Activation of the acid sphingomyelinase in platelets by tumor cells is 
mediated by P-selectin as shown by the failure of P-selectin-deficient platelets to stimulate 
the acid sphingomyelinase and to release ceramide.  This demonstrates a novel function of 
ceramide in the activation of platelets, and a novel mechanism of tumor metastasis.   
 
In order to identify signal transduction events that mediate the activation of 
thrombocytes by tumor cells and their metastatic capabilities, the activity of the acid 
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sphingomyelinase was measured after incubation with purified B16F10 tumor cells.   Co-
incubation of wild type platelets with B16F10 tumor cells over a time course up to 1 
minute showed that within the first 5 seconds the acid sphingomyelinase in the 
thrombocytes was stimulated, and this activity peaked after 10 seconds of the begin of the 
interaction between tumor cells and thrombocytes.  60 seconds after tumor cell:platelet 
interaction the activity of acid sphingomyelinase returned to base line levels.  Co-
incubation of thrombocytes purified from acid sphingomyelinase-deficient mice with 
B16F10 melanoma cells did not reveal any additional activity of the acid 
sphingomyelinase compared to baseline activity, indicating that by incubation of 
thrombocytes with B16F10 melanoma cells the raised activity of the acid 
sphingomyelinase enzyme is due to the acid sphingomyelinase in the thrombocytes and 
not the tumor cells.   
 
 
4.2.2  Acid sphingomyelinase activity and ceramide production 
 
 The activation of the acid sphingomyelinase correlated with the production of ceramide 
after stimulation of the thrombocytes with B16F10 melanoma cells.  The formation of 
ceramide was determined by the DAG kinase assay after stimulation of thrombocytes with 
tumor cells.  Compared to wild-type thrombocytes, acid sphingomyelinase-deficient 
thrombocytes failed to release ceramide.  This shows that the release of ceramide after co-
incubation of tumor cells with thrombocytes is dependent on the expression of acid 
sphingomyelinase in thrombocytes.   
 
It has been shown that P-selectin deficiency abrogates tumor metastasis in mice, 
indicating that P-selectin plays a key role in tumor metastasis.  It is a novel finding that a 
link has been established between P-selectin-deficiency and the release of ceramide.  In 
this study P-selectin-deficient thrombocytes were co-incubated with B16F10 melanoma 
cells over a time course.  As wild-type platelets from C57/Bl6 mice showed an activation 
of the acid sphingomyelinase where the acid shingomyelinase activity peaked after 10 
seconds of co-incubation with B16F10 melanoma cells and declined thereafter, reaching 
baseline levels again after app. 30 seconds, thereby indicating a rapid activation, P-
selectin-deficient thrombocytes showed an acid sphingomyelinase activity at baseline 
Discussion 
  60 
levels (Figure 4). The activation of acid sphingomyelinase in wild-type thrombocytes 
correlated with the release of ceramide, peaking after app. 15 seconds and declining 
thereafter, while co-incubation of ASM-deficient thrombocytes with melanoma cells 
failed to release ceramide (Figure 5).  It can be concluded that since there is no acid 
sphingomyelinase activity, the deficiency of activity of the enzyme is therefore the cause 
of the failure of ceramide release from sphingomyelin. 
 
 
4.2.3  B16F10 tumor cells also activate platelets via pathways independent of P-
selectin 
 
To exlude the possibility that the failure of activation of the acid sphingomyelinase and 
the subsequent release of ceramide in P-selectin-deficient thrombocytes is due to 
inhibition of thrombocyte:tumor cell contact and interaction, it was determined whether P-
selectin-deficient thrombocytes and wild-type thrombocytes exhibited cellular tyrosine 
phosphorylation as well as activity of PLCγ, JNK and MAPK after co-incubation of the 
thrombocytes with tumor cells.  The signaling events were stimulated in wild-type as well 
as P-selectin-deficient thrombocytes, indicating that the tumor cells interacted with wild-
type as well as P-selectin-deficient thrombocytes and hitherto activate either set albeit one 
being P-selectin-deficient.  In fact, Figure 10 indicates that there is no difference in 
tyrosine phosphorylation, activation of PLCγ, MAPK, and JNK, in wild-type 
thrombocytes compared to P-selectin-deficient thrombocytes upon co-incubation thereof 
with B16F10 melanoma cells, indicating that B16F10 tumor cells are also able to activate 
platelets via pathways that are independent of P-selectin.  Generally, these enzymes are 
typical markers of cellular activation and represent major signaling pathways in many 
cells.  MAP kinase is a threonine/serine specific protein kinase that responds to 
extracellular stimuli (mitogens) and regulates various cellular activities such as gene 
expression, mitosis, differentiation and cell survival or apoptosis (Springer, 1995).  The 
extracellular stimuli activate MAP kinase by a signaling cascade, being phosphorylated on 
its serine and threonine residues.  MAP kinases are involved in the action of most non-
nuclear oncogenes and are responsible for cell response to growth factors.  JNK are 
involved in a signaling cascade, being activated by stress factors like UV-radiation, 
interleukins, or chemokines, amongst others.  The targets of JNK are proteins within the 
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cellular nucleus, esp. the phosphorylation of c-JUN that regulates gene expression as 
apoprotein-1, proteins of the cytoskeleton, as well as members of the BH3 family, where 
the latter inactivates the anti-apoptotic Bcl-2 by phosphorylation, and pro-apoptotic 
proteins like Bax are activated.  PLCγ is part of a G-protein-coupled receptor signal 
transduction pathway and is activated by transmembrane receptors with intrinsic or 
associated tyrosine kinase activity.  PLCγ hydrolyzes phosphatidylinositol into two second 
messengers, inositol triphosphate and diacylglycerol (DAG).  These products then 
modulate the activity of downstream proteins during cellular signaling like calcium 
channels in the endoplasmic reticulum of several different cell types and protein kinase C.  
PLCγ requires calcium for catalytic activity and is activated by receptor tyrosine kinase.   
 
 
4.2.4  Platelets degranularize independently of P-selectin 
 
When activated, thrombocytes degranularize and expose P-selectin, stored in the 
intracellular alpha granules, on the cellular surface, as well as GPIIbIIIα, a platelet-
specific receptor.  When wild-type thrombocytes are activated in co-incubation with 
B16F10 melanoma cells, they rapidly degranularize and reduce in size (Figure 12).  
Degranularization exposes GPIIbIIIα and P-selectin on the extracellular surface, as 
determined by specific antibodies.  Degranularization of thrombocytes and their size 
reduction also occurs in thrombocytes deficient for acid sphingomyelinase, indicating that 
the translocation of P-selectin and GPIIbIIIα occurs independently of the presence of acid 
sphingomyelinase.   
 
Since P-selectin is expressed both on endothelial cells as well as thrombocytes, it was 
determined by transplantation experiments that wild-type bone marrow reconstituted the 
ability in P-selectin-deficient mice to form metastases.  Since deletion of P-selectin in 
thrombocytes abolished tumor metastasis of intravenously injected tumor cells in wild-
type mice, and deficiency of endothelial cell P-selectin (P-selectin-deficient mice) 
reconstituted tumor metastasis, it indicates that thrombocytic P-selectin plays a significant 
role in tumor metastasis of B16F10 melanoma cells in the lung, while endothelial P-
selectin is of less importance, at least under these circumstances.  
 
Discussion 
  62 
4.2.5  Fucoidan binds and blocks P-selectin 
 
It stands to reason that blocking P-selectin protein on thrombocytes could be of great 
medical importance in the course of cancer treatment.  P-selectin binds sulfated molecules 
such as heparin and sulfatides (Varki, 1994; Crocker and Feizi, 1996).  All selectins bind 
with higher affinity to only a few glycoproteins on leukocytes or endothelial cells.  These 
glycoproteins must be sialylated and fucosylated to interact with selectins.  For P- and L-
selectins, they must be sulfated (Imai et al., 1993; Hemmerich et al., 1994; Wilkins et al., 
1995; Pouyani and Seed, 1995; Sako et al., 1995; Li et al., 1996), and binding requires 
sialylated and fucosylated O-glycans.  Fucoidan is a sulfated polysaccharide present in 
brown seaweed, and it has been reported (Durig et al., 1997; Patankar et al., 1993) to be a 
heparin-like molecule.  Fucoidan has anti-coagulatory properties (Durig et al., 1997; 
Trento et al., 2001) and inhibitory effects on tube formation of human endothelial cells 
(Soeda et al., 2000) in addition to anticancer effects through modulation of host immune 
systems (Riou et al., 1996; Itoh et al., 1993; Zhuang et al., 1995; Koyanagi et al., 2003).  
In this study, fucoidan was injected into mice shortly before injection of B16F10 
melanoma cells.  The results show that fucoidan inhibited tumor metastasis, most likely by 
interfering with thrombocytic P-selectin.  As P-selectin is blocked by action of this 
sulfated polysaccharide, thrombocytes no longer are able to bind tumor cells by P-selectin, 
and the tumor cell:thrombocyte complex can no longer bind endothelial P-selectin and 
initiate rolling under shear stress and eventually halt on the inner lining of the vasculature.  
Therefore, extravasation does not take place with the effect of a decreased amount of 
metastases in the lungs of mice.    
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4.3 Ceramide, its Metabolites and Selectins  
 
4.3.1 Ceramide triggers the release of Weibel-Palade P-Selectin 
 
 
Current knowledge about the function of the acid sphingomyelinase, ceramide and its 
metabolites sphingosine and sphingosine-1-phosphate in platelets is limited.  It has 
previosly been demonstrated that thrombin induces a release of the acid sphingomyelinase 
from platelets, but the functional consequences of acid sphingomyelinase secretion are not 
yet defined.  Further studies suggested that sphingosine and sphingosine-1-phosphate 
support the aggregation of platelets, while the role of ceramide in platelet aggregation 
remains undefined.  Endogenous ceramide triggers the release of P-selectin by Weibel-
Palade body exocytosis (Bhatia et al., 2004). 
 
Ceramide and its metabolites mediate vascular inflammation by increasing endothelial 
cell expression of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion 
molecule, thereby inducing leukocyte and monocyte adhesion to the vascular wall (Kim et 
al., 2001; Xia et al., 1998; Modur et al., 1996).  These activated leukocytes and 
macrophages secrete cytokines that further induce inflammation and cytokine production.  
Ceramide is involved in generation of reactive oxygen species which can lead to 
inflammation and tissue injury (Bhunia et al, 1997).  By triggering Weibel-Palade body 
exocytosis, ceramide increases endothelial P-selectin expression, which can induce 
leukocyte adhesion and aggregation to the vascular wall. Weibel-Palade bodies are located 
in endothelial cells only, therefore P-selectin expression is limited to that cell type.  There 
is no evidence of yet that ceramide triggers the release of P-selectin in thrombocytes 
consistent with our findings.    
 
 
4.3.2  Ceramide and reactive oxygen species  
 
Oxidative stress occurs when the production of reactive oxygen species (ROS) exceeds 
the capacity of the cell to detoxify these potentially injurious oxidants using endogenous 
antioxidant defense systems. Conditions associated with oxidative stress include 
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ischemia/reperfusion, hypercholesterolemia, diabetes, and hypertension. The adhesion of 
circulating blood cells (leukocytes, platelets) to vascular endothelium is a key element of 
the pro-inflammatory and prothrombogenic phenotype assumed by the vasculature in 
these and other disease states that are associated with an oxidative stress. There is a 
growing body of evidence that links the blood cell endothelial cell interactions in these 
conditions to the enhanced production of ROS.  Potential enzymatic sources of ROS 
within the microcirculation include xanthine oxidase, NAD(P)H oxidase, and nitric oxide 
synthase. ROS can promote a pro-inflammatory/prothrombogenic phenotype within the 
microvasculature by a variety of mechanisms, including the inactivation of nitric oxide, 
the activation of redox-sensitive transcription factors (e.g., nuclear factor-kappa B) that 
govern the expression of endothelial cell adhesion molecules (e.g., P-selectin), and the 
activation of enzymes (e.g., phospholipase A(2)) that produce leukocyte-stimulating 
inflammatory mediators (e.g., platelet-activating factor). The extensively documented 
ability of different oxidant-ablating interventions to attenuate blood cell:endothelial cell 
interactions underscores the importance of ROS in mediating the dysfunctional 
microvascular responses to oxidative stress.   
 
 
4.4  Clinical Relevance of P-selectin-Mediated Acid Sphingomyelinase 
Activation in Tumor Metastasis 
 
This study shows that metastasis of B16F10 melanoma cells requires an acid 
sphingomyelinase-triggered activation of platelets.  Mice genetically deficient for acid 
sphingomyelinase are almost completely protected from tumor metastasis, indicating that 
pathophysiological significance of platelet acid sphingomyelinase for tumor metastasis in 
vivo.  P-selectin mediates the activation of the acid sphingomyelinase as is shown by 
failure of P-selectin-deficient thrombocytes to stimulate the acid sphingomyelinase, 
release ceramide and develop lung metastases in vivo once challenged with melanoma 
cells.  This study also indicates a novel function of ceramide in that it activates platelets 
by P-selectin.  In melanoma cells, the course of metastasis is initiated by the binding of 
tumor cells by P-selectin ligands present on the surface of the tumor cells to platelets.  
This binding results in an intracellular activation of the platelets, indicating that the 
function of P-selectin is not merely adhesion but also serves as a receptor molecule that is 
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able to transmit signals into platelets. Thus far, it is unknown how P-selectin couples to 
acid sphingomyelinase and thereby mediates the release of ceramide.  Activation of the 
acid sphingomyelinase appears to be independent of tyrosine kinases because activation of 
the acid sphingomyelinase is abrogated by deficiency of P-selectin while tumor cells elicit 
cellular tyrosine phosphorylation independent of P-selectin in platelets.   
  
It has been demonstrated (Aigner et al., 1998) that thrombin induced a release of acid 
sphingomyelinase from platelets, although the functional consequences of its secretion 
remained undefined.  Furthermore, sphingosine and sphingosine-1-phosphate support 
aggregation of platelets, while the role of ceramide in platelets has not been well defined.  
In cellular stimulation, acid sphingomyelinase has the general function  to form ceramide-
enriched membrane platforms that function to reorganize and cluster receptor molecules.  
Therefore, it can be concluded that acid sphingomyelinase and ceramide are not 
necessarily a part of the specific signaling cascade initiated by the activated receptor, but 
instead facilitate receptor signaling through ceramide-enriched membrane platforms by 
providing cellular conditions that allow receptors to transmit a specific signal.  In the case 
of P-selectin, ceramide-enriched membrane platforms in platelets may re-organize and 
cluster the P-selectin molecules and/or receptors in the cellular membrane, resulting in a 
higher density of receptor molecules within a defined space in the platelet cellular 
membrane.  This may facilitate and enhance contact between platelets, exposing P-selectin 
ligands and/or other receptor ligands, and endothelial cells, leading to a thrombus 
formation and finally the extravasation of the tumor cells.  The increased receptor density 
in ceramide-enriched membrane platforms might be imperative to permit contact between 
platelets and endothelial cells even under shear stress as is present in the capillaries.  It is 
not ruled out, however, that endogenous ceramide or its metabolites sphingosine or 
sphingosine-1-phosphate directly induce platelet aggregation by unknown intermediates, 
thereby forming the thrombus.  Also, ceramide might change the conformation of 
adhesion receptors and increase the affinity to their ligands, resulting then in a thrombus 
formation.  There is no mutual exclusion between the models, and it is possible that a 
combination of mechanisms mediates platelets and tumor cell adhesion to endothelial 
cells. 
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Clinically, in this study a link has been established that connects P-selectin-activated 
acid sphingomyelinase with tumor metastasis.  The molecular mechanisms of tumor 
metastasis are currently not well understood, yet especially tumor metastasis is of great 
importance in the course of human cancer.  The present studies identified the acid 
sphingomyelinase as a novel target molecule for the inhibition of tumor metastasis.  
Pharmaceutical agents that act on acid sphingomyelinase, i.e. acid sphingomyelinase 
inhibitors, could be utilized during surgical procedures with tumors or patients with 
tumors who exhibit high risk of tumor metastasis. 
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Summary 
 
 
 
The present manuscript demonstrates that B16F10 melanoma cells activate the enzyme 
acid sphingomyelinase in thrombocytes via the surface molecule P-selectin, by which 
ceramide is released.  Metastasis of tumor cells in the lung is decreased by up to 95% by 
genetic deficiency of P-selectin molecule or deficiency of acid sphingomyelinase.  After 
activation of wild type thrombocytes by B16F10 melanoma cells there is a rapid increase in 
acid sphingomyelinase activity and ceramide production as compared to acid 
sphingomyelinase-deficient thrombocytes or P-selectin-deficient thrombocytes.  A lack of 
interaction of B16F10 melanoma cells and thrombocytes was excluded by activation of PLCγ, 
JNK and MAP kinase, indicating that these signaling events are stimulated in both, wild-type 
and P-selectin-deficient platelets, proving that B16F10 melanoma cells interact with and 
activate P-selectin-deficient thrombocytes.   
 
The molecular mechanisms of tumor metastasis are currently fairly incomplete, though 
metastasis plays a crucial clinical role in cancer patients.  Acid sphingomyelinase is 
iidentified as a novel target molecule for the inhibition of tumor metastasis.  In order to 
pharmacologically inhibit the thrombocytic P-selectin system, an intravenous injection of 
fucoidan showed a decrease of tumor metastasis of B16F10 melanoma cells by approximately 
75%.  This indicates that tumor metastasis can be blocked pharmacologically, which is of 
great clinical interest.   
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